Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 1 of 58 Clinical Trial Protocol: THR -1442 -C-453 
Study Title: A phase 1, open-label, randomized, t hree-period, crossover study to 
evaluate pharmacokinetic interacti on between bexagliflozin tablets and 
metformin, glimepiride, or sitagliptin in healthy subjects 
Study Number: THR-1442-C-453 
Study Phase: 1 
Product Name: Bexagliflozin tablets 
IND Number: 103822 
Indication: Type 2 Diabetes Mellitus 
Investigators: Single center 
Sponsor: Theracos Sub, LLC 
Sponsor Contact: Albert Collinson, Ph.D. 
Theracos Sub, LLC. 
225 Cedar Hill Street, Suite 200 , Marlborough, MA 01752 
Phone: 508 -688-4221 
e-mail: acollinson@theracos.com 
Sponsor Study 
Representative: Annie L. Conery, Ph.D. 
185 Cambridge Street , Boston, MA 02114 
Phone: 617 -726-5930, Fax: 617-643-8203 
e-mail: aconery@mgh.harvard.edu  
Medical Monitor: Mason W. Freeman, MD 
185 Cambridge Street, Boston, MA 02114  
Phone: 617 -724-7704, Fax: 617-643-8203 
e-mail: mfreeman@ccib.mgh.harvard.edu 
 
 Date 
Original Protocol: 01 September 2016 
Confidentiality Statement 
The information contained in this protocol is confidential and provided only to the 
investigators, clinical study collaborators, investigational drug managers, study sites and 
institutional review boards  participating in the study. The information may, therefore, not be, 
disclosed to any third party except for subjects when receiving their consent, or used for 
purposes other than this study without the written consent of Theracos Sub, LLC.  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 2 of 58 TABLE OF CONTENTS  
SYNOPSIS ...................................................................................................................... ...........6  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ..........................................10  
1 INTRODUCTION ...........................................................................................................12  
2 STUDY OBJECTIVES ....................................................................................................13  
2.1 Primary Objective ..................................................................................................13  
2.2 Secondary Objective ..............................................................................................13  
3 INVESTIGATIONAL PLAN ..........................................................................................14  
3.1 Overall Study Design and Plan ..............................................................................14  
3.2 Rationale for Study Design and Control Group .....................................................15  
3.2.1  Rationale for Study Design ..........................................................................15  
3.2.2  Rationale for Dose Selection .......................................................................15  
3.2.3  Rationale for PK and PD Sampling Time Points .........................................16  
3.3 Study Duration and Dates ......................................................................................16  
4 STUDY POPULATION SELECTION ...........................................................................17  
4.1 Study Population ....................................................................................................17  
4.2 Inclusion Criteria ...................................................................................................17  
4.3 Exclusion Criteria ..................................................................................................17  
5 STUDY TREATMENTS .................................................................................................19  
5.1 Description of Treatments......................................................................................19  
5.1.1  Investigational products ...............................................................................19  
5.1.2  Oral Hypoglycemic Agents..........................................................................19  
5.1.2.1  Metformin ..........................................................................................19  
5.1.2.2  Glimepiride ........................................................................................19  
5.1.2.3  Sitagliptin ...........................................................................................19  
5.2 Treatments Administered .......................................................................................19  
5.3 Selection and Timing of Dose for Each Subject ....................................................20  
5.3.1  Group 1: Bexagliflozin and Metformin .......................................................20  
5.3.2  Group 2: Bexagliflozin and Glimepiride .....................................................20  
5.3.3  Group 3: Bexagliflozin and Sitagliptin ........................................................20  
5.4 Method of Assigning Subjects to Tr eatment Groups and Sequences ....................21  
5.5 Blinding..................................................................................................................21  
5.6 Concomitant Therapy.............................................................................................21  
5.7 Restrictions ............................................................................................................21  
5.7.1  Prior Therapy ...............................................................................................21  
5.7.2  Fluid and Food Intake ..................................................................................21  
5.7.3  Subject Activity Restrictions .......................................................................22  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 3 of 58 5.8 Treatment Compliance ...........................................................................................22  
5.9 Packaging and Labeling .........................................................................................22  
5.10  Storage and Accountability ....................................................................................22  
6 STUDY PROCEDURES .................................................................................................23  
6.1 Informed Consent...................................................................................................23  
6.2 Medical History .....................................................................................................23  
6.3 Physical Examination.............................................................................................24  
6.4 Vital Signs ..............................................................................................................24  
6.5 Electrocardiography ...............................................................................................24  
6.6 Clinical Laboratory Tests .......................................................................................25  
6.6.1  Laboratory Parameters .................................................................................25  
6.6.2  Sample Collection, Storage, and Shipping ..................................................26  
6.6.2.1  Hematology and Blood Chemistry.....................................................26  
6.6.2.2  Urinalysis ...........................................................................................26  
6.6.2.3  Urine Collection .................................................................................26  
6.6.2.4  Plasma Sample Collection for PK ......................................................26  
6.7 Adverse Events Assessments .................................................................................26  
6.7.1  Collecting and Reporting Adverse Events ...................................................28  
6.7.2  Immediately Reportable Adverse Events .....................................................29  
6.7.3  Pregnancy .....................................................................................................29  
6.7.4  Follow-up of Adverse Events ......................................................................30  
6.7.4.1  Follow-up of Non-serious Adverse Events ........................................30  
6.7.4.2  Follow-up of Post-Study Serious Adverse Events .............................30  
6.7.4.3  Hepatotoxicity ....................................................................................30  
6.7.4.4  Hypoglycemia ....................................................................................31  
6.8 Concomitant Medication Assessments ..................................................................31  
6.9 Removal of Subjects from the Trial or  Discontinuation of Investigational 
Product ...................................................................................................................32  
6.10  Appropriateness of Measurements .........................................................................33  
7 STUDY ACTIVITIES .....................................................................................................34  
7.1 Screening (Days -28 to Day -1) .............................................................................34  
7.2 Period 1 ..................................................................................................................34  
7.2.1  Day 0 (Clinic Admission) ............................................................................34  
7.2.2  Day 1 (Dosing Day): Pre-dose Activities ....................................................35  
7.2.3  Day 1 (Dosing Day): Dosing .......................................................................35  
7.2.4  Day 1: Post-dose Activities ..........................................................................36  
7.2.5  Day 2: Post-dose Activities ..........................................................................36  
7.2.6  Day 3: Post-dose Activities ..........................................................................36  
7.2.7  Day 4 (Group 3 Only): Post-dose Activities ................................................37  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 4 of 58 7.3 Period 2 ..................................................................................................................37  
7.3.1  Day 7 (Clinic Admission) ............................................................................37  
7.3.2  Day 8 (Dosing Day): Pre-dose Activities ....................................................37  
7.3.3  Day 8 (Dosing Day): Dosing .......................................................................38  
7.3.4  Day 8 (Dosing Day): Post-dose Activities ...................................................38  
7.3.5  Day 9: Post-dose Activities ..........................................................................38  
7.3.6  Day 10: Post-dose Activities ........................................................................39  
7.3.7  Day 11 (Group 3 Only): Post-dose Activities ..............................................39  
7.4 Period 3 ..................................................................................................................40  
7.4.1  Day 14 (Clinic Admission) ..........................................................................40  
7.4.2  Day 15 (Dosing Day): Pre-dose Activities ..................................................40  
7.4.3  Day 15 (Dosing Day): Dosing .....................................................................40  
7.4.4  Day 15 (Dosing Day): Post-dose Activities .................................................41  
7.4.5  Day 16: Post-dose Activities ........................................................................41  
7.4.6  Day 17: Post-dose Activities ........................................................................41  
7.4.7  Day 18 (Group 3 Only): Post-dose Activities ..............................................42  
7.5 Early Termination or Follow-up Procedures .........................................................42  
8 QUALITY CONTROL AND ASSURANCE .................................................................43  
9 PLANNED STATISTICAL METHODS ........................................................................44  
9.1 General Considerations ..........................................................................................44  
9.2 Determination of Sample Size ...............................................................................44  
9.3 Analysis Populations ..............................................................................................44  
9.3.1  Safety Population .........................................................................................44  
9.3.2  PK Population ..............................................................................................44  
9.3.3  PD Population ..............................................................................................44  
9.4 Demographics and Baseline Characteristics ..........................................................44  
9.5 Pharmacokinetic Analysis ......................................................................................45  
9.5.1  Calculation of Pharmacokinetic Variables ...................................................45  
9.5.2  Statistical Analysis of Pharmacokinetic Variables ......................................46  
9.6 Pharmacodynamic Analysis ...................................................................................46  
9.7 Safety Analysis ......................................................................................................47  
9.7.1  Adverse Events ............................................................................................47  
9.7.2  Hypoglycemia ..............................................................................................47  
9.7.3  Clinical and Laboratory Events and Analyses .............................................47  
9.7.4  Concomitant Medications ............................................................................48  
10 ADMINISTRATIVE CONSIDERATIONS ....................................................................49  
10.1  Investigators and Study Administrative Structure .................................................49  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 5 of 58 10.2  Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 
Approval ................................................................................................................49  
10.3  Ethical Conduct of the Study .................................................................................49  
10.4  Subject Information and Consent...........................................................................50  
10.5  Subject Confidentiality ..........................................................................................50  
10.6  Study Monitoring ...................................................................................................50  
10.7  Case Report Forms and Study Records .................................................................51  
10.8  Protocol Violations/Deviations ..............................................................................51  
10.9  Access to Source Documentation ..........................................................................51  
10.10  Retention of Data ...................................................................................................52  
10.11  Publication and Disclosure Policy .........................................................................52  
11 REFERENCE LIST .........................................................................................................53  
 
LIST OF IN-TEXT TABLES 
Table 1.  Treatment Sequences .................................................................................14  
Table 2.  Required Laboratory Tests .........................................................................25  
 
LIST OF APPENDICES 
Appendix 1  Schedule of Events .....................................................................................54  
Appendix 2  Sponsor Signatures.....................................................................................57  
Appendix 3  Investigator’s Signature  .............................................................................58  
 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 6 of 58 SYNOPSIS 
Sponsor: 
Theracos Sub, LLC 
Name of Finished Product: 
Bexagliflozin tablets 
Name of Active Ingredient: 
Bexagliflozin 
Name of Inactive Ingredients: 
Polyethylene oxide, glyceryl behenate, lactose monohydrate, micronized poloxamer 188, 
microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate (vegetable 
grade). The tablets are film-coated with Opad ry II Blue with no markings on the tablets. 
Study Title: 
A phase 1, open -label, randomized, three-period, crossover study to evaluate 
pharmacokinetic interaction between bexagliflo zin tablets and metformin, glimepiride, or 
sitagliptin in healthy subjects  
Study Number: 
THR-1442-C-453 
Study Phase: 1 
Primary Objective:  
To evaluate the drug -drug interaction of co- administration of bexagliflozin with commonly 
prescribed oral hypoglycemic agents (OHAs) metformin, glimepiride, or sitagliptin on the pharmacokinetics (PK) of be xagliflozin and each OHA 
Secondary Objective: 
To evaluate the safety, tolerability, and pharmacodynamics (PD) of bexagliflozin when it is 
co-administered with commonly prescribed OHAs  
Study Design: 
In this study, a total of 54 healthy subjects will be enrolled and assigned to one of three 
groups of eighteen. Each group will participate in one of three open -label, randomized, three-
period, three -treatment crossover studies: 
Group  1: Bexagliflozin/metformin drug-drug interaction (DDI) 
Group  2: Bexagliflozin/glimepiride DDI 
Group  3: Bexagliflozin/sitagliptin DDI 
Within each study, subjects will be randomized to one of six treatment sequences in an equal 
ratio. Each subject will receive a single dose of bexagliflozin tablet, 20 mg, alone, a single dose of an OHA (1000 mg metformin, 4 mg glimepiride or 100 mg sitagliptin) alone, and the 
combination of both (bexagliflozin tablet and OHA)  alternately in a crossover fashion, with 
three treatment periods separated by a washout period of at least 7 days. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 7 of 58 To prevent hypoglycemia, subjects assigned to  Group 2 (bexagliflozin/glimepiride DDI) will 
receive 240 mL of a 20% glucose solution in water with study medication at the time of 
dosing, as well as 60 mL of a 20% glucose solution in water every 15 min for 4 hours post-
dose. 
For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 
(bexagliflozin/glimep iride DDI), subjects will be admitt ed to the clinic on the day before 
dosing and will stay in the clinic until 48 h post -dose. For Group 3 (bexagliflozin/sitagliptin 
DDI), subjects will be admitted to the clinic on the day before dosing and will stay in the 
clinic until 72 h post -dose. 
For all Groups, blood samples for PK analysis will be collected in each period prior to dosing 
(pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3, 
PK blood samples will also be collected at 60 and 72 h post -dose. 
Urine samples for PD analysis will be collected in 12 h intervals . For all Groups, urine 
samples will be collected pre -dose (-12 to 0 h) and post-dose a t 0 to 12 h, 12 to 24 h, 24 to 36 
h, and 36 to 48 h . For Group 3, additional samples at 48 to 60 h and 60 to 72 h post- dose will 
be collected.  
Clinical laboratory tests and safety monitori ng will be conducted during all treatment 
periods. 
Study Population:  
Approximately 54 healthy male and female subjects are planned to be enrolled. 
Diagnosis and Main Criteria for Inclusion 
1. Male and female subjects who are between 18 to 65 years of age, inclusive, in good 
health based on medical history, physical examina tion (PE), electrocardiogram (ECG) 
and routine laboratory tests. 
2. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive.  
3. Subjects who are non-smokers for at least 3 months prior to screening. 
4. Subjects with adequate venous access at multiple sites in both arms. 
5. Subjects who are willing and able to be confined to the clinical research facility as 
required by the protocol. 
6. Subjects who have the ability to compre hend and who are willing to provide written 
informed consent in accordance with institutional and regulatory guidelines. 
Test Product, Dose, and Mode of Administration: 
Bexagliflozin tablets, 20 mg, single dose per treatment period, oral administration 
Reference Therapy, Dose, and Mode of Administration: 
Metformin, 1000 mg, single dose per treatment period, oral administration 
Glimepiride, 4 mg, single dose  per treatment period, oral administration 
Sitagliptin, 100 mg, single dose per treatment period, oral administration 
Duration of Treatment:  
After subjects are screened and  randomized, the duration of the study will be up to 22 days 
from the day of initial investigational product administration. There will be 3 treatments 
separated by a washout period of at least 7 days. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 8 of 58 Pharmacokinetic Assessment: 
The following PK paramete rs of bexagliflozin and the OH As will be determined when 
feasible after each subject is dosed with bexagliflozin, an OHA or a combination of both:  
Cmax     Maximum observed plasma concentration 
Tmax      Time of maximum observed plasma concentration 
Oz           Terminal el imination phase rate constant  
T½           Apparent terminal elimination half-life 
CL/F      Apparent oral clearance  
Vz/F     Apparent volume of distribution 
AUC 0-t    Area under the plasma concentration-time curve from Time 0 to Time t (time of  
last quantifiable plasma concentration) 
AUC 0-∞  Area under the plasma concentration-time curve from Time 0 to infinity 
Pharmacodynamic Assessment: 
Urinary glucose excretion (UGE) will be derived from the urine samples collected in 12 -hour 
batches in study subjects administered bexagliflozin or OHA a lone or bexagliflozin with an 
OHA  in combination. UGE t1-t2 (mg) will be derived from urine volume (V t1-t2, mL) x glu cose 
concentration (mg/dL)/100.  
Safety  Assessments: 
• Vital signs 
• Clinical laboratory tests including blood chemistry and hematology parameters 
• Urinalysis  
• Adverse events 
• Concomitant medication use 
Statistical Methods:  
Statistical analysis will be performed using Statistical Analysis Software SAS for Windows® 
(SAS Institute Inc., USA). PK parameters of bexagliflozin will be calculated by non -
compartmental analysis (NCA) of plasma concentration -time data. Non-compartmental 
analysis will be performed using Phoenix® WinNonlin® 6.4 (Certara, USA). To assess the 
effect of OHAs metformin, glimepiride or sita gliptin on the PK of bexagliflozin and vice  
versa, an analyses of variance (ANOVA)  using a linear mixed- effects model will be fitted to 
the natural logarithmic transformation of PK parameters of bexagliflozin (C max, AUC 0-t and 
AUC 0-∞). The linear mixed-effects model will in clude subject as a random effect, and 
treatment, period, and sequence as fixed effe cts. The 90% confidence intervals will be 
constructed for the (bexagliflozin and OHA in  combination) to (bexagliflozin alone) or 
(OHA alone) ratio of the least squares (LS) geometric means of PK parameters ( Cmax, AUC 0-t 
and AUC 0-∞), with 80-125% defined as the lack of interaction boundaries. 
Descriptive statistics for the PK parameters C max, Tmax, AUC 0-∞, AUC 0-t , CL/F, V z/F, λz and 
T1/2 will be tabulated by treatment. Mean s, standard deviations, medians, ranges (min, max) 
and geometric means and coefficients of variati on will be presented for all PK parameters 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 9 of 58 with exception of T max. Medians and ranges will be presented for T max. 
Descriptive statistics on the PD parameters will be also performed. The effect of OHA alone, 
bexagliflozin alone and OHA and bexagliflozin in combination  on the cumulative UGE of 
healthy subjects will be compared.  
Date of Original Protocol:  01 September 2016 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 10 of 58 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
AE adverse event 
ALT alanine aminotransferase 
ANOVA analysis of variance 
AST aspartate aminotransferase 
AUC area under the plasma concentration-time curve 
AUC extr % of AUC 0-∞ due to extrapolation from T last to infinity 
AUC 0-∞ area under the plasma concentration-ti me curve from time 0 to infinity 
AUC 0-t area under the plasma concentration -time curve from time 0 to time t (time of last 
quantifiable plasma concentration) 
BMI body mass index 
BLOQ below level of quantification 
BP blood pressure 
Cmax maximum plasma drug concentration 
Clast concentration corresponding to T last 
CL/F apparent oral clearance 
CRF case report form 
CRO contract research organization 
DDI drug-drug interaction 
DPP-4 dipeptidyl peptidase 4 
ECG electrocardiogram 
eGFR estimated glomerular filtration rate 
FPG fasting plasma glucose 
GCP Good Clinical Practice 
GMI genital mycotic infection 
HBsAg hepatitis B surface antigen 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
ICH International Council on Harmonisation  
IEC Independent Ethics Committee 
IRAE immediately reportable adverse event 
IRB Institutional Review Board 
K2EDTA potassium ethylenediaminetetraacetic acid 
LS least squares  
λz terminal elimination phase rate constant 
MedDRA Medical Dictionary for Regulatory Activities 
NCA non-compartmental analysis 
OHA oral hypoglycemic agent 
OTC over-the-counter 
PD pharmacodynamic 
PE physical examination 
PK pharmacokinetic 
SAE serious adverse event 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 11 of 58 SD standard deviation 
SFU sulfonylurea 
SGLT2 sodium glucose cotransporter 2 
SOP standard operating procedure 
TEAE treatment emergent adverse event 
T1/2 terminal elimination half life 
Tlast time of last measurable concentration 
Tmax time to maximum plasma concentration 
T2DM type 2 diabetes mellitus 
UGE urine glucose excretion 
ULN upper limit of normal 
UTI urinary tract infection 
Vz/F apparent volume of distribution 
WHO-DD World Health Organization Drug Dictionary 
WOCBP women of child-bearing potential 
  
Definitions of Terms 
Study  The THR -1442-C-453 study refers to all activities within the protocol. Within THR-1442 -C-
453, there are 3 open -label, randomized, three-period, th ree-treatment crossover studies. 
Each of the 3 studies will enroll a Group of 18 subjects (see Group below). 
Group  The 54 subjects in the THR -1442-C-453 study will be assigned to one of 3 groups of 18 
subjects. Each Group will be treated with bexagliflozin and one of the three oral 
hypoglycemic agents (OHAs), metformin (Group 1), sitagliptin (Group 2), or glimepiride 
(Group 3). 
Sequence  Each Group of 18 subjects will be randomized to participate in 1 of 6 treatment sequences 
with 3 subjects in each sequence. Each sequ ence will have a different order of 3 possible 
treatments: bexagliflozin alone, OHA alone, or bexagliflozin and OHA in combination. 
Period  Each Sequence will have 3 treatment periods. Du ring each Period, subjects will receive 1 of 
3 possible treatments (bexagliflozin alo ne, OHA alone, or bexagliflozin and  OHA in 
combination). 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 12 of 58 1 INTRODUCTION 
Diabetes mellitus, a metabolic disease character ized by prolonged hyperglycemia, is one of 
the leading causes of morbidity and mortality worldwide, affecting an estimated 387 million people as of 2014 (IDF, 2014). More than 95% of people with diabetes have type 2 diabetes mellitus (T2DM) (IDF, 2014).  
Several classes of oral agents are availab le for treating T2DM, including biguanides, 
sulfonylureas (SFU), or dipeptidyl peptidase-4 (DPP-4) inhibitors. Metformin (a biguanide), sitagliptin (an SFU) and glimep iride (a DDP-4 inhibitor) are 3 commonly prescribed oral 
hypoglycemic agents (OHAs) with different mechanism of actions (Tahrani et al., 2016). Metformin is the first-line treatment for T2DM that works by increasing insulin sensitivity of 
body tissues and decreasing glucose production by  the liver. Sitagliptin causes elevation of 
circulating incretins, which results in enhanced nutrient-induced insulin secretion. Glimepiride increases secretion of insulin by the pancreas.  
Sodium glucose cotransporter 2 (SGLT2) inhibito rs are a new class of OHAs that targets the 
renal Na+/glucose transport protein, SGLT2. SGLT2 inhibitors increase excretion of glucose in the urine and thereby lower fasting and pos t-prandial glucose levels. SGLT2 inhibitors 
increase urinary glucose excretion without increa sing insulin secretion, causing weight gain, 
or inducing hypoglycemia (Nauck, 2014). 
Bexagliflozin is a candidate OHA that is a poten t and highly specific inhibitor of SGLT2. 
(Zhang et al., 2011). Bexagliflozin has been shown to cause dose-dependent increases in urinary glucose excretion (UGE) in humans, rats, dogs and monkeys and to reduce HbA1c in 
animal models of T2DM and in diabetic  subjects. Detailed information regarding 
bexagliflozin clinical studies and potential risks for study subjects are provided in the Investigator’s Brochure.  
Bexagliflozin is cleared predominantly by metabolism to an inactive metabolite, 
bexagliflozin 3-O-glucuronide by uridine diphosphate glucuronosyltransferase isoform 1A9 (UGT1A9) pathway. 
The aim of the study is to evaluate potential drug-drug interaction (DDI) effects on the 
pharmacokinetics (PK) and pharmac odynamics (PD) of co-admin istration of bexagliflozin 
with three commonly prescribed OHAs, i.e., metformin, glimepiride, or sitagliptin. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 13 of 58 2 STUDY OBJECTIVES 
2.1 Primary Objective  
The primary objective of this study is to evaluate whether drug-drug interactions following 
co-administration of bexagliflozin with commonly prescribed OHAs metformin, glimepiride, or sitagliptin result in any change in the PK of bexagliflozin or each of the OHAs. 
2.2 Secondary Objective 
The secondary objective of this study is to evaluate the safety, tolerability, and PD of bexagliflozin following single dose administration of the drug in combination with commonly prescribed OHAs. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 14 of 58 3 INVESTIGATIONAL PLAN 
3.1 Overall Study Design and Plan 
In this study, a total of 54 healthy subjects wi ll be enrolled and assigned to three groups of 
eighteen. Each group will participate in one of three open-label, three treatment period, 
crossover studies: 
Group 1: Bexagliflozin/metformin drug-drug interaction (DDI) 
Group 2: Bexagliflozin/glimepiride DDI Group 3: Bexagliflozin/sitagliptin DDI  
For each Group, every subject will receive a single dose of bexagliflozin tablet, 20 mg, alone, 
a single dose of an OHA (1000 mg metformin, 4 mg glimepiride or 100 mg sitagliptin) alone, and the combination of both (bexagliflozin tablet and OHA) alternately in a crossover 
fashion, in three treatment periods separated by  a washout period of at least 7 days. Within 
each Group, subjects will be randomized to one of  six treatment sequences in an equal ratio 
as shown in Table 1. 
Table 1. Treatment Sequences 
Treatment Sequence Treatment  Period 1 Treatment Period 2 Treatment  Period 3 
1 Bexa alone1 OHA alone2 Bexa  + OHA 
2 Bexa alone  Bexa  + OHA OHA alone  
3 OHA alone  Bexa alone  Bexa  + OHA 
4 OHA alone  Bexa  + OHA Bexa alone  
5 Bexa  + OHA OHA alone  Bexa alone  
6 Bexa  + OHA Bexa alone  OHA alone  
1 Bexa: bexagliflozin; OHA: oral hypoglycemic agent 
 
To prevent hypoglycemia, subjects assigned to Group 2 will receive a 20% oral glucose 
solution with study medication at the time of dos ing, as well as a 20% glucose solution every 
15 min for 4 hours post-dose. 
During each treatment period for Group 1 (bexagliflozin/metformin DDI) and Group 2 
(bexagliflozin/glimepiride DDI), subjects will be admitted to the clinic on the day before 
dosing and will stay in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), subjects will stay in the clinic until 72 h post-dose. 
For Group 1 and 2, blood samples for PK analysis will be collected in each period prior to 
dosing (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For 
Group 3, PK blood samples will also be collected at 60 and 72 h post-dose. Plasma 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 15 of 58 concentrations of bexagliflozin and OHAs will be determined by validated liquid 
chromatography tandem mass spectrometry (LC-MS/MS) assays. 
Urine samples for PD analysis will be collec ted in 12 h intervals. For Group 1 and 2, urine 
samples will be collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 
h, and 36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose will be collected. 
Clinical laboratory tests and safety monitoring will be conducted during all treatment periods 
as is outlined in Appendix 1  Schedule of Events. 
3.2 Rationale for Study Design and Control Group 
3.2.1 Rationale for Study Design 
Each of the 3 Groups within THR-1442-C-453 will  participate in a ra ndomized, three-period, 
three-treatment crossover study. This design  was chosen to properly separate treatment 
effects from period effects. 
Three commonly prescribed OHAs, metformin, sitag liptin and glimepiride, were chosen for 
the THR-1442-C-453 study.  
Sitagliptin does not undergo extensive metabolism. After oral exposure, the parent drug 
comprises the majority of plasma and urinary drug concentrations (Vincent et al., 2007). Sitagliptin metabolites were detected in small amounts and in vitro  experiments found that 
CYP3A4 and, to a lesser extent, CYP2C8, were the major CYP isozymes responsible for the 
limited metabolism (Vincent et al., 2007). Me tformin also does not undergo significant 
metabolism, and both metformin and sitagliptin ar e eliminated unchanged in urine via tubular 
secretion and glomerular filtration (Pentika inen et al., 1979). Glimepiride is mainly 
metabolized by CYP2C9 and the metabolites are excreted in urine (Langtry and Balfour, 1998).  
The metabolic pathway for bexagliflozin is di fferent from that of the 3 OHAs (metformin, 
sitagliptin, and glimepiride), which suggests a low potential for metabolic drug-drug interaction between bexagliflozin and the OHAs being tested. In vitro  metabolism studies 
demonstrated that bexagliflozin is not a potent inhibitor or inducer of CYP450 enzymes. UGT1A9 is principally responsible for the glucuronidation of bexagliflozin. In the urine, unchanged parent drug accounted for less than 2% of the dose.  
3.2.2 Rationale for Dose Selection 
Bexagliflozin produces a dose-dependent, satura ble increase in UGE in healthy volunteers 
and diabetic subjects. Population pharmacodynamic modeling has indicated that bexagliflozin doses of 20 mg result in 90% of  the maximal UGE. In a long term treatment 
study, daily administration of 20 mg bexagliflozin was found to reduce HbA1c by 0.79% 
compared to placebo at week 24. In additi on, adverse events (AEs), particularly those 
involving urinary tract infection (UTI) and genital mycotic infection (GMI), were found to be 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 16 of 58 similar between placebo and active agent cohorts . To evaluate the drug-drug interaction of 
co-administration of bexagliflozin with metformi n, glimepiride, or sitagliptin, bexagliflozin 
tablets, 20 mg, which is intended to be the commercial product, will be administered in this trial. 
The dosages for the OHAs are equivalent to the highest single tablet dose available for each 
OHA (1000 mg metformin, 4 mg glimepiride or 100 mg sitagliptin), and are within recommended daily dose ranges. 
3.2.3 Rationale for PK and PD Sampling Time Points 
The T
½ of bexagliflozin is 7.80 to 9.71 h, and T ½ of metformin and glimepiride are 4-9 h and 
5-9 h, respectively. Based on the biological half-lives of the study drugs, the PK sampling 
time points for Group 1 (bexagliflozin/metf ormin DDI) and Group 2 (bexagliflozin/ 
glimepiride DDI) are pre-dose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), two additional PK sampling time points, at 60 and 72 h post-dose, will be added as the T
½ for sitagliptin is 12.4 h. 
Urine samples for PD analysis will be collected  in 12 h intervals from -12 h pre-dose to 48 h 
post dose (-12 to 0 h, 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h) for Groups 1 and 2, and additional samples at 48 to 60 h and 60 to 72 h post-dose will be collected for Group 3. 
3.3 Study Duration and Dates 
Subjects will be screened within 28 days of the planned initiation of investigational product 
dosing. Eligible subjects who consent to the study will be assigned to 1 of 3 Groups. Subjects 
in each Group will be randomly assigned to re ceive 1 of 6 treatment regimens in a crossover 
fashion with three treatment periods separated by a washout period of at least 7 days. Up to 2 additional washout days will be allowed. 
For each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 
(bexagliflozin/glimepiride DDI), subjects will be admitted to the clinic on the day before 
dosing (day 0 for treatment period 1, day 7 for treatment period 2 and day 14 for treatment period 3) and will stay in the cl inic until 48 h post-dose. For Group 3 
(bexagliflozin/sitagliptin DDI), subjects will be admitted on the day before dosing (day 0 for 
treatment period 1, day 7 for treatment period 2 and day 14 for treatment period 3), but will stay in the clinic until 72 h post-dose. 
The duration of the overall study from screening until study termination is estimated to be a 
maximum of 50 days. For details of the schedule and nature of the investigations, see the 
Schedule of Events in Appendix 1 . 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 17 of 58 4 STUDY POPULATION SELECTION 
4.1 Study Population 
Fifty-four eligible healthy male and female subjec ts who consent to participate in this study 
will be enrolled. 
4.2 Inclusion Criteria 
Each subject must meet the following cr iteria to be enrolled in this study. 
1. Male and female subjects who are between 18 to 65 years of age, inclusive, in good 
health based on medical history, physical examination (PE), electrocardiogram (ECG) 
and routine laboratory tests. 
2. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2, inclusive. 
3. Subjects who are non-smokers for at least 3 months prior to screening. 
4. Subjects with adequate venous access at multiple sites in both arms. 
5. Subjects who are willing and able to be confined to the clinical research facility as 
required by the protocol. 
6. Subjects who have the ability to comprehend and who are willing to provide written 
informed consent in accordance with institutional and regulatory guidelines. 
 
4.3 Exclusion Criteria 
Subjects who meet any of the following criteria will be excluded from the study. 
1. Subjects who are determined by the investigator or sub-investigator to be unsuitable for 
participating in the study based on medical conditions or factors that would influence adherence to study activities. 
2. Subjects with a clinically significant history of allergy to drugs or latex. 
3. Subjects with a history of alcohol or drug dependence in the last 12 months. 
4. Subjects who have donated 400 mL of whole blood within 56 days, 200 mL of whole 
blood within one month, or donated blood components within 14 days of screening. 
5. Subjects who have used prescription or over-the-counter (OTC) drugs within 14 days 
prior to the first dose. 
6. Subjects who have used vitamin preparations wi thin 7 days or supplements (including St. 
John ’s Wort and ginseng) within 14 days prior to the first dose. 
7. Subjects who have undergone strenuous physica l activity within 72 hours prior to dosing 
in each period. 
8. Subjects who have been treated with an investigational drug within 30 days or 7 half-
lives of the investigational drug, whichever is longer, prior to the first dose of 
investigational drug in this trial. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 18 of 58 9. Subjects who had previously received EGT0001474 or bexagliflozin, or any other 
SGLT2 inhibitors within 3 months from sc reening or have participated in previous 
bexagliflozin clinical trials., regardless of whet her they received bexagliflozin or placebo 
in those trials. 
10. Subjects who had previously received OHAs, including metformin, sitagliptin, 
glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), within 3 months of screening. 
11. Subjects whose screening ECG demonstrates any one of the following: heart rate > 100 
bpm, QRS > 120 msec, QTc > 470 msec (corrected by Bazett’s formula) , PR > 220 msec 
(a subject with PR > 220 msec will generally be excluded but exceptions may be allowed at the discretion of the investigator), or any clinically significant arrhythmia. 
12. Subjects whose sitting blood pressure is above 140/90 mmHg at screening.  If the sitting 
blood pressure at screening is above 140/90 mmHg, one repeat measurement is allowed 
and the subject may be randomized if the repeat screening blood pressure is 140/90 +/-5 mmHg at the discretion of the Investigator. 
13. Subjects who have a positive result of hepati tis B surface antigen (HBsAg), hepatitis C 
virus (HCV) antibody, urinary drug or urinary cotinine test. 
14. Subjects with known human immunodeficiency virus (HIV) infection. 
15. Subjects who have had a febrile illness w ithin 5 days prior to the first dose of 
investigational drug. 
16. Subjects vaccinated (with the exception of the flu vaccine) within 30 days prior to the 
first dose of investigational drug. 
17. Subjects with estimated glomerular filt ration rate (eGFR) < 90 mL/min/1.73 m
2 or a 
history of kidney transplant. 
18. Male subjects who do not agree to refrain from donating sperm and use appropriate birth 
control such as the use of condoms when engaging in sexual intercourse for a period of 30 days after discharge from the clinic. 
19. Female subjects of childbearing potential who are not willing to use an adequate method 
of contraception and to not become pregnant for the duration of the study. Female subjects who are surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses greater than 12 months a nd age > 45 years) are eligible if they test 
negative on the urine pregnancy test. 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 19 of 58 5 STUDY TREATMENTS 
5.1 Description of Treatments 
5.1.1 Investigational products 
Bexagliflozin tablets, 20 mg, are blue caplet-sha ped, film-coated tablets that are intended for 
use in investigational studies in humans. The tablets contain excipients designed to promote 
extended release through a gastroretentive mecha nism. The active tablets exhibit a greater 
than 75% release of drug substance by 8 hours in simulated gastric fluid in vitro . 
5.1.2 Oral Hypoglycemic Agents 
Three OHAs that are frequently prescribed in patients with T2DM are included in the study. 
5.1.2.1 Metformin 
Metformin is a biguanide, which decreases hepatic glucose production and may improve 
peripheral glucose uptake and utilization. After oral administration, metformin is absorbed from the gastrointestinal tract. Metformin is excreted unchanged in the urine and does not 
undergo hepatic metabolism or biliary excretion. 
5.1.2.2 Glimepiride 
Glimepiride is a 2nd generation SFU, which stimulates gl ucose-independent insulin release 
from the pancreas. After oral administration, glimepiride is absorbed from the 
gastrointestinal tract. Glimepiride is metaboliz ed mostly by hepatic P450 enzyme CYP2C9.  
5.1.2.3 Sitagliptin 
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. After oral administration, sitagliptin 
is absorbed from the gastrointestinal tract. Si tagliptin is metabolized by hepatic P450 enzyme 
CYP3A4 and CYP2C8. 
5.2 Treatments Administered 
Subjects who consent to be in the study will be assigned to 1 of 3 groups. Each subject will receive a single oral dose of bexagliflozin tablet, 20 mg, alone, a single dose of one other OHA alone, and the combination of both (bexagliflozin tablet and OHA) alternately in a 
crossover fashion in three treatment periods sepa rated by a washout period of at least 7 days:  
Group 1: Bexagliflozin tablet, 20 mg, and metformin, 1000 mg 
Group 2: Bexagliflozin tablet, 20 mg, and glimepiride, 4 mg Group 3: Bexagliflozin tablet, 20 mg, and sitagliptin, 100 mg 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 20 of 58 5.3 Selection and Timing of Dose for Each Subject 
Dosing order with bexagliflozin alone, OHA alone, or bexagliflozin in combination with 
OHA will be based on randomized assign ment. Bexagliflozin and OHAs will be 
administered with 240 mL of liquid (water for Group 1 and 3, 20% glucose solution for Group 2). If for some reason, a portion of the liquid is not consumed, the reason and the 
amount of remaining liquid will be recorded. 
5.3.1 Group 1: Bexagliflozin and Metformin 
• Bexagliflozin alone : After an overnight fast of at least 10 hours, a bexagliflozin tablet, 
20 mg, will be administered before the first meal of the day with 240 mL of water. 
• Metformin alone : After an overnight fast of at le ast 10 hours, metformin, 1000 mg, will 
be administered before the first meal of the day with 240 mL of water.  
• Co-administration of bexagliflozin and metformin : After an overnight fast of at least 
10 hours, a bexagliflozin tablet, 20 mg, and metformin, 1000 mg, will be administered 
before the first meal of the day with 240 mL of water. 
 
5.3.2 Group 2: Bexagliflozin and Glimepiride 
• Bexagliflozin alone : After an overnight fast of at least 10 hours, a bexagliflozin tablet, 
20 mg, will be administered before the first meal of the day with 240 mL 20% glucose 
solution in water. Subjects will be administ ered 60 mL of 20% glucose solution in water 
every 15 minutes during the first 4 hours following administration of bexagliflozin. 
• Glimepiride alone : After an overnight fast of at least 10 hours, glimepiride, 4 mg, will 
be administered before the first meal of the day with 240 mL of 20% glucose solution in 
water. Subjects will be administered 60 mL  of 20% glucose solution in water every 15 
minutes during the first 4 hours following administration of glimepiride. 
• Co-administration of bexagliflozin and glimepiride : After an overnight fast of at least 
10 hours, a bexagliflozin tablet, 20 mg, and glimepiride, 4 mg, will be administered 
before the first meal of the day with 240 mL of 20% glucose solution in water. Subjects will be administered 60 mL of 20% glucose so lution in water every 15 minutes during the 
first 4 hours following administration of bexagliflozin and glimepiride. 
 
5.3.3 Group 3: Bexagliflozin and Sitagliptin 
• Bexagliflozin alone : After an overnight fast of at lea st 10 hours, a bexagliflozin tablet, 
20 mg, will be administered before the first meal of the day with 240 mL of water. 
• Sitagliptin alone : After an overnight fast of at leas t 10 hours, sitagliptin, 100 mg, will be 
administered before the first meal of the day with 240 mL of water.  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 21 of 58 • Co-administration of bexagliflozin and sitagliptin : After an overnight fast of at least 
10 hours, a bexagliflozin tablet, 20 mg, and sitagliptin, 100 mg, will be administered 
before the first meal of the day with 240 mL of water.  
 
5.4 Method of Assigning Subjects to Treatment Groups and 
Sequences 
A total of 54 healthy subjects will be enrolled  and assigned to one of three groups of 
eighteen. Each group of eighteen will be ra ndomized to 1 of 6 possible treatment sequences. 
Subjects who discontinue the study early will not be replaced.  
5.5 Blinding 
This is an open-label study. 
5.6 Concomitant Therapy 
The participants are not allowed to take any pr escription or non-prescription drugs, or dietary 
supplements at any time during the 14 days prior  to first drug administration and for the 
duration of all three study periods. Vitamins can be taken up to 7 days prior to first study drug administration.  No other concomitant med ications are permitted with the exception of 
those required for treatment of an AE. Subjects may receive any medications for AEs that are necessary to control or minimize the likelihood of more serious adverse events in the investigators’ judgment.  
Concomitant medications administered at the time of randomization and during the study are 
to be recorded on the case report form (CRF). The medication name, dose, frequency, route of administration, date(s) of admi nistration and reason for admi nistration must be recorded. 
This documentation should continue until the end of the last study period. Medications that a subject receives after entering the study and pr ior to randomization must be recorded in the 
CRF. 
5.7 Restrictions 
5.7.1 Prior Therapy 
No study subject shall have been dosed with any SGLT2 inhibitor within 3 months prior to 
the screening, nor with an investigational drug within 30 days or 7 half-lives, or used any 
prescription medication or herbal supplements within 14 days prior to the first dose of study 
medication. 
5.7.2 Fluid and Food Intake  
An overnight fast of at least 10 h prior to dosin g is required. Water is permitted during the 
fasting period up to 1 hour prior to and after the administration of each investigational 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 22 of 58 product administration. Adequate hydration is encouraged during each study period. Food 
can be consumed 4 h after dosing. 
• Bexagliflozin will be taken before the first meal of the day with 240 mL of water, except 
during Group 2 (bexagliflozin/glimepiride DDI) when bexagliflozin will be administered 
with 240 mL 20% glucose solution in water and 60 mL 20% glucose solution in water 
every 15 minutes during the first 4 hours following administration of bexagliflozin.  
• Metformin will be taken before the first meal of the day with 240 mL of water.  
• Glimepiride will be taken before the first meal of the day with 240 mL 20% glucose 
solution in water and 60 mL of 20% glucose solution in water will be provided every 15 
minutes during the first 4 hours following administration of glimepiride. 
• Sitagliptin will be taken before the first meal of the day with 240 mL of water. 
 
5.7.3 Subject Activity Restrictions 
Light physical activity is permitted. Subjec ts should not perform strenuous activity which 
could result in elevations of muscle creatine kinase levels. Smoking during the study is prohibited. 
5.8 Treatment Compliance 
To ensure compliance, all medication dosing will be supervised by the Investigator or qualified staff in the clinic. The exact times of dosing will be recorded in the CRFs, including 
a record of checks followed by hand mouth inspection. 
5.9 Packaging and Labeling 
Bexagliflozin tablets, 20 mg, are packaged in high density polyethylene bottles sealed with a child resistant closure. The product is packaged with 90 tablets per bottle. 
Investigational product bottles will be labeled wi th protocol number, drug name and strength, 
lot number, sponsor’s name , storage condition, and the investigational drug caution 
statement. 
5.10 Storage and Accountability 
Drug supplies should be stored at controlled room temperature (15°  to 30°C) in a secure area 
with access limited to authorized personnel. The sponsor will perform an ongoing inventory 
of study products. The responsible pharmacist must keep a careful inventory of drug shipments received and the number of tablets dispensed per study subject. A full reconciliation of drug inventory will be performe d at the end of the study and the results of 
this inventory must be recorded in the Drug  Accountability Form. Empty and partially used 
bottles may be discarded after use according to the study sites’ regulations for the disposal of 
investigational drug substances at study close out, after the Drug Accountability Form is 
completed. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 23 of 58 6 STUDY PROCEDURES 
6.1 Informed Consent 
Before each subject is enrolled in the clinical study, written informed consent will be 
obtained from the subjects according to the regulatory and legal requirements. As part of this procedure, the investigator 
or designee must explain orally and in writing the nature, duration, 
and purpose of the study, and the action of the drug in such a manner that the study subject is aware of the potential risks, inconveniences, or AEs that may occur. The investigator should educate potential subjects about the scientific  importance of their data and the vital role that 
their participation has for the outcome of the entire study. The subject must be informed that he/she is free to withdraw from the study at any time. He/she will receive all information that 
is required by federal regulations and In ternational Council on Harmonisation (ICH) 
guidelines. 
The informed consent document must be signed and dated. One copy will be given to the 
subjects, and the investigator will retain a copy as part of the clinical study records. The investigator will not undertake any investigation specifically required for the clinical study until written consent has been obtained. The terms of the consent and when it was obtained must also be documented. 
6.2 Medical History 
The following information will be collected at the screening visit:  
• Demographic information including age, sex, and race. 
• Significant medical, surgical history and ti meframe of the history relative to study 
screening, if applicable. 
• Clinically significant history of allergy including drugs and latex. 
• History of smoking in the last 3 months, and alcohol or drug dependence, or abuse in the 
last 12 months. 
• Any blood donation within 56 days or blood component donation within 14 days. 
• Use of any medications including OTC drugs, or dietary supplements in the last 14 days. 
Use of any vitamins in the last 7 days. 
• History of vaccination (except the flu vaccine) within 30 days prior to the first dose of 
study medication. 
• History of diagnosis with HIV, hepatitis B or hepatitis C. 
• Use of any investigational drug in the previous 30 days or 7 half-lives, whichever time 
frame is longer. 
• Prior exposure to bexagliflozin (or EGT0001474), or any other SGLT2 inhibitors in the 
last 3 months. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 24 of 58 • Prior exposure to metformin, sitagliptin, glimepiride, or drugs of the same class 
(biguanides, DPP-4 inhibitors, or sulfonylureas) in the last 3 months. 
 
6.3 Physical Examination 
The investigator or designated qualified individua l will perform the PEs. A complete PE will 
be performed at screening and on the last day of period 3 prior to discharge. Partial PEs will 
be performed at scheduled visits. 
A complete PE will include measurement of body weight and height (height will be 
measured only at screening), general assessment of all body systems including the skin, head, eyes, ears, nose, throat, neck, lungs, heart, abdomen, lymph nodes, and extremities. A partial 
PE will include body weight and an update of the general assessment of the skin, heart, lungs 
and abdomen. 
6.4 Vital Signs 
Vitals signs, including pulse, systolic and diastolic blood pressure (BP), respiration rate, and oral temperature, will be measured at the scheduled visits described in Appendix 1 .  
Vital signs should be measured prior to blood draws. Pulse, systolic and diastolic BP should be measured in a seated position after a subject has 
been sitting for 5 minutes. 
Respiration rate should be measured after at least 5 minutes of rest.  
BP measures will be obtained using a calibrated sphygmomanometer. Devices designed to 
measure BP from the finger or wrist may not be used. 
6.5 Electrocardiography 
A 12-lead ECG will be conducted as listed in Appendix 1  and whenever clinically indicated. 
This procedure should be performed in the supine  position after at least 5 minutes of rest. 
ECG parameters measured will be the RR inte rval, PR interval, QRS duration, and QT. Each 
ECG should also be assessed by the investigator for signs of ischemia, clinically significant hypertrophy, and clinically significant T-wave abnormalities. 
It is the investigator 
or designee ’s responsibility to review the results of the ECG as they 
become available. For each abnormal ECG result, the investigator needs to ascertain if this is a clinically significant change from the screening ECG for that individual subject. This determination, however, does not necessarily need  to be made the first time an abnormal 
result is observed. The investigator may repeat the ECG to verify the results of the original result. If the ECG result is determined to be a clinically significant and an abnormal change 
from baseline for that subject, this is considered an AE. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 25 of 58 6.6 Clinical Laboratory Tests 
6.6.1 Laboratory Parameters 
Subjects will be in a seated or in a supi ne position during blood collection. Clinical blood 
chemistry and hematology tests will be performed at the scheduled visits ( Appendix 1 ). 
Blood samples should be drawn after overnight fa sting prior to breakfast. The details of the 
required laboratory tests are listed in Table 2. 
Table 2. Required Laboratory Tests 
Test Name  mL (sample) 
Hematology 4.0 (blood) 
Hematocrit  
Hemoglobin  
Mean corpuscular hemoglobin  
Mean corpuscular hemoglobin concentration  Mean corpuscular volume 
Platelet count  
Red blood cell count  
White blood cell count with differential   
Serum Chemistry and Electrolytes  5.0 (serum) 
Albumin  
Alanine aminotransferase (ALT)  
Aspartate aminotransferase (AST)  
Blood urea nitrogen  
Glucose  
Bicarbonate  
Creatinine  
Chloride 
Total protein Calcium 
Magnesium  
Phosphorus  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin  
Uric acid   
Serum Lipids  3.5 (serum) 
Total cholesterol  
High -density lipoprotein cholesterol 
Triglycerides Low-density lipoprotein cholesterol, 
calculat ed 
  
Urinalysis  20 (urine) 
Appearance  
Bilirubin  
Color  
Glucose  
Ketones  
Microscopic examination of sediment  Nitrite  
pH 
Protein  
Specific gravity  
Urobilinogen  
Leukocyte esterase  
Urine Collection (in 12 -h batches) 
Glucose  
Creatinine  
 All (urine)  
Urine Drug Screen  10 (urine) 
Amphetamines  
Barbiturates  
Cocaine Metabolites  
Cotinine Opiates 
Benzodiazepines  
Cannabinoids   
Urine Pregnancy Test (Female only)  5 (urine) 
Infectious Disease Testing  5.0 (serum) 
Hepatitis B surface antigen (HBsAg) Hepatitis C virus (HCV)   
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 26 of 58 6.6.2 Sample Collection, Storage, and Shipping 
6.6.2.1 Hematology and Blood Chemistry 
Blood samples for hematology and chemistry will  be collected. Timing  of the collection is 
described in Appendix 1 . 
6.6.2.2 Urinalysis 
Clean-catch, midstream urine samples will  be collected per schedule outlined in Section 7  
and in Appendix 1 . Dipstick urinalysis will be conducted. Microscopy will be obtained if the 
subject has a positive result on any of the dipstick  tests that require microscopic follow-up to 
clarify their significance. In addition, urinalysi s will be performed from a clean-catch urine 
sample at any time in subjects with symptoms of UTI or pyelonephritis. 
6.6.2.3 Urine Collection 
Pre-dose urine samples must be collected from -12 to 0 h for baseline measurement. Subjects 
will empty their bladders prior to dosing. Post-dose urine will be collected without 
preservative in four (4) batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h collections.  Post-dose urine will be collected in six (6) batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h, 48 to 60 h and 60 to 72 h. Urine must be refrigerated at 2-8
oC during collection. After collection, the total volume of each batch and collection 
time will be recorded. A 20 mL aliquot will be  prepared from well mixed urine collections. 
The samples will be analyzed for urinary glucose (for PD analysis) and creatinine. 
6.6.2.4 Plasma Sample Collection for PK  
Whole venous blood samples of 5 mL will be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2.  PK blood samples will  be collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 
16, 24, 36, 48, 60 and 72 h post-dose for Group 3.  Bl ood samples will be collected in tubes 
containing potassium ethylenediaminetetraacetic acid (K
2EDTA) and stored on ice until 
centrifuged under refrigeration for at least 10 min at 3,000 rpm. After centrifugation, plasma will be removed, divided into 2 aliquots of approximately 1 mL, frozen and stored at or 
below -20°C.  Plasma should be processed and frozen within 2 h of blood collection. Processed frozen plasma samples will be transf erred on dry ice to the analytical laboratory 
and will be stored at or below -20
oC until analysis. 
6.7 Adverse Events Assessments 
Adverse Event (AE ): Any untoward medical occurrence in clinical investigation subject 
administered a pharmaceutical product. An AE do es not necessarily have to have a causal 
relationship with this treatment. 
An AE can therefore be any unfavorable a nd unintended sign (including an abnormal 
laboratory finding, for example), symptom, or di sease temporally associated with the use of 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 27 of 58 an investigational product, whether or not it is  considered related to the investigational 
product. 
Serious Adverse Event (SAE): A serious adverse event (experience) or reaction is any 
untoward medical occurrence that at any dose: 
• results in death, 
• is life-threatening (NOTE: The term "life-threatening" in the definition of "serious" refers 
to an event in which the patient was at risk of death at the time of the event and does not 
refer to an event which hypothetically might have caused death if it were more severe.), 
• requires inpatient hospitalization or prolongation of existing hospitalization, 
• results in persistent or significant disability/incapacity, 
• is a congenital anomaly/birth defect, 
• is an important medical event. 
 
An important medical event is an event that may not be immediately life-threatening or result 
in death or hospitalization but may jeopardize  the patient or may require intervention to 
prevent one of the other outcomes listed in th e definition above. Examples of such events are 
intensive treatment in an emergency room  or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result  in hospitalization, or development of drug 
dependency or drug abuse. 
Non-serious adverse events are all events that do not meet the criteria for a "serious" adverse 
event. 
Immediately Reportable Adverse Event (IRAE):  Any serious adverse event or any 
adverse event that necessitates discontinuation of investigational product. 
Clinical Laboratory Changes:  It is the investigator’s responsibility to review the results of 
all laboratory tests as they become available. For each abnormal laboratory test result, the investigator needs to ascertain if this is a clinically significant change from baseline for that individual subject. This determination, however, does not necessarily need to be made the first time an abnormal value is observed. The investigator may repeat the laboratory test or request additional tests to verify the results of the original laboratory tests. If this laboratory value is determined to be an abnormal change  from baseline for that subject, this is 
considered an AE. 
Hypoglycemia will be defined as any fasting plasma glucose (FPG) value < 70 mg/dL and 
documented as described in Section 6.7.4.4.  
Any increase in liver function tests (aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), or bilirubin) greater than 3 times the upper limit of normal (ULN) 
for the laboratory utilized will be considered a clinical laboratory adverse event. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 28 of 58 An increase in creatinine from baseline by 0.5 mg/dL or more will be reported as a laboratory 
adverse event. 
Severity:  Adverse events will be graded on a 3-point scale and reported as indicated on the 
CRF. The intensity of an adverse experience is defined as follows: 
1 = Mild: discomfort noticed, but no disruption to daily activity 2 = Moderate: discomfort sufficient to reduce or affect normal daily activity 3 = Severe: inability to work or perform normal daily activity Investigational Product Causality:  The site and database should ask for the causality 
relative to the study compound. Relationship of an adverse event to dosing will be assessed 
as follows: 
Definite: There is a reasonable causal relationship between the investigational product and 
the AE when the event responds to withdrawal of the investigational product (dechallenge), and recurs with administration of th e investigational product (rechallenge). 
Probable: There is a reasonable causal relati onship between the investigational product and 
the AE. The event responds to dechallenge. Rechallenge is not required. 
Possible: There is a reasonable causal relationship between the investigational product and 
the AE. Dechallenge is lacking or unclear. 
Not Likely: There is a temporal relationship to investigational product administration, but 
there is not a reasonable causal relationship between the investigational product and the 
event. 
Unrelated: There is no temporal or causal  relationship to investigational product 
administration. 
6.7.1 Collecting and Reporting Adverse Events 
Adverse event collection will begin on the first clinical admission day (Day 0). The 
investigator will periodically assess subjects for the occurrence of adverse events. To avoid 
bias in collecting information about adverse events, the investigator should ask subjects the 
following question: "How have you felt since you were last checked?" All adverse events 
(serious and non-serious) reported by the subject must be recorded on the source documents 
and CRFs provided by the sponsor. 
In addition, Theracos’ Medical Monitor or its designated personnel must be notified 
immediately by telephone or fax of any immediately reportable adverse events according to the procedure outlined below. Special attention should be paid to recording hospitalization and concomitant medications. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 29 of 58 6.7.2 Immediately Reportable Adverse Events 
The investigator must report any serious SAE, by telephone, email, or fax, to Theracos or its 
representative immediately after the investigator becomes aware of the event. An IRAE form should be completed and sent by email or fax or overnight courier to the sponsor within 24 h of knowledge of the event. 
Non-serious events that require discontinuation of investigational product (including 
laboratory abnormalities) should be reported to Theracos within 3 working days. The IRAE form should be completed and sent by email or fax or overnight courier to the sponsor. 
Subjects experiencing an SAE should be followed clinically until their health has returned to 
baseline status or until all parameters have re turned to normal, or have otherwise been 
explained. It is expected that the investigat or will provide or arrange appropriate supportive 
care for the subject. 
6.7.3 Pregnancy 
Women of childbearing potential (WOCBP) who ar e sexually active must use an effective 
method of birth control during the course of the study, in a manner such that risk of failure is minimized. 
Before enrolling WOCBP in this clinical trial, investigators must review guidelines about 
study participation for WOCBP. The topics should generally include: 
1. General information. 
2. Informed consent form. 
3. Pregnancy prevention information. 
4. Drug interactions with hormonal contraceptives. 
5. Contraceptives in current use. 
6. Guidelines for the follow-up of a reported pregnancy. 
 Prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy. The 
subject must sign an informed consent form stating the above-mentioned risk factors and that the consequences were discussed with her. 
During the study, all WOCBP should be instructed to contact the investigator immediately if 
they suspect they might be pregnant (e.g., missed or late menstrual cycle). 
If a subject or investigator suspects that the subject may be pregnant prior to investigational 
product administration, the investigational product administration must be withheld until the results of serum pregnancy tests are available. If the pregnancy is confirmed, the subject must not receive the investigational product and must not remain in or be enrolled in the study. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 30 of 58 The investigator must notify the Medical Monitor within 3 working days of the receipt of 
information that any female subject who has become pregnant.  
The investigator must record the event on the Pregnancy Surveillance Form and forward it to 
the sponsor’s clinical or designated personnel.  
6.7.4 Follow-up of Adverse Events 
6.7.4.1 Follow-up of Non-serious Adverse Events 
Non-serious adverse events that are identified on the last scheduled contact must be recorded 
on the AE CRF with the current status noted. A ll non-serious events that are ongoing at the 
time will be recorded as ongoing on the CRF. 
6.7.4.2 Follow-up of Post-Study Serious Adverse Events 
SAEs that are identified on the last scheduled contact must be recorded on the AE CRF page and reported to Theracos according to the reporting procedures outlined in Section 6.7.1 . 
These may include unresolved previously reported SAEs, or new SAEs. The investigator should follow these subjects until the events are resolved, or the subject is lost to follow-up. Resolution means the subject has returned to th e baseline state of health, or the investigator 
does not expect any further improvement or worsening of the subject’s condition. The investigator should continue to report any significant follow-up information to Theracos until the event has been resolved. 
Any new SAEs reported by the subject to the investigator that occur after the last scheduled 
contact, and are determined by the investigator to be reasonably associated with the use of 
the investigational product, should be reported to the Medic al Monitor or the sponsor’s 
designated personnel. These may include SAEs that are captured on follow-up telephone contact or at any other time point after the de fined study period (i.e., up to last scheduled 
contact). The investigator should follow subjects with  SAEs identified after the last 
scheduled contact until the events are resolved, or the subject is lost to follow-up. The investigator should continue to report any significant follow-up information to the Sponsor until the event has been resolved. This study requires that subjects be actively monitored for SAEs for  at least 14 days after discharge from the study. 
6.7.4.3 Hepatotoxicity 
Any clinically significant increase in hepatic enzymes and specifically ALT or AST ≥ 3x 
ULN requires immediate repeat test within 48 to 72 h to confirm the hepatic enzyme 
elevation. Study medication should be stopped and the event should be reported as an adverse event within the CRF if the enzyme elevation is confirmed or worsening. Potential contributors to hepatic enzyme elevation s hould be evaluated by the investigator. The 
investigator is encouraged to consult with the Medical Monitor regarding ongoing diagnostic workup. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 31 of 58 Investigational product should be permanently discontinued if any of the following criteria is 
met: 
• ALT or AST > 8xULN, 
• ALT or AST > 3xULN and (total bilirubin > 2xULN or INR > 1.5), 
• ALT or AST > 3xULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, feve r, rash, and/or eosinophilia (> 5%). 
 
6.7.4.4 Hypoglycemia 
Hypoglycemia will be recorded under 5 categories: 
• Critical hypoglycemia: An event requiring a ssistance of another person to actively 
administer carbohydrate, glucagons, or other re suscitative actions. These episodes may be 
associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucose 
measurements may not be available during such an event, but neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration. All such events should be recorded as seri ous adverse events in the CRF. 
• Documented symptomatic hypoglycemia: An event during which typical symptoms of 
hypoglycemia are accompanied by a measured plasma glucose concentration ≤ 70 m g/dL 
(3.9 mmol/L). 
• Asymptomatic hypoglycemia: An event not accompanied by typical symptoms of 
hypoglycemia but with a measured plasma glucose concentration ≤ 70 mg/dL 
(3.9 mmol/L). 
• Probable symptomatic hypoglycemia: An event during which symptoms of hypoglycemia 
are not accompanied by a plasma glucose determination but that was presumably caused 
by a plasma glucose concentration ≤ 70 mg/dL (3.9 mmol/L).  
• Relative hypoglycemia: An event during which the person with diabetes reports any of 
the typical symptoms of hypoglycemia, and interprets those as indicative of 
hypoglycemia, but with a measured plasma glucose concentration > 70 mg/dL (3.9 mmol/L). 
 
6.8 Concomitant Medication Assessments 
A concomitant medication is any medication the subject enters the trial taking and is 
expected to continue taking for some portion of the trial, as well as any medication the 
subject takes during the course of the trial. All prescription and over-the-counter medications, including vitamins and herbal supplements, that subjects receive during the trial must be documented on the CRF. This documentation should continue until the subjects are 
discharged. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 32 of 58 Concomitant medications will be coded us ing the World Health Organization Drug 
Dictionary (WHO-DD). A table of concomitant medications based on the anatomic therapeutic chemical classification and pr eferred name will be produced. A listing of 
concomitant medications will include all medicat ions taken by any subjects during the course 
of the study. 
Concomitant medications administered during th e study are to be recorded on the CRF. The 
medication name, dose, frequency, route of ad ministration, date(s) of  administration and 
reason for administration must be recorded. This documentation should continue until discharge from the study. 
6.9 Removal of Subjects from the Trial or Discontinuation of 
Investigational Product 
The investigator must emphasize to poten tial subjects the im portance of continued 
participation for the full duration of the tr ial during the informed consent process. 
Participation in the study is voluntary. A participant has the right to withdraw from the study at any moment for any reason. The investigator will be informed immediately. 
The investigator has the right to terminate participat ion of a subject in case it is difficult to 
obtain blood samples, in case of violation of the protocol or in case of severe or serious adverse events. 
In case a subject withdraws from the study, th e study monitor will be informed immediately. 
If there is a medical reason for withdrawal, the volunteer should remain under the supervision of the medical investigator until satisfactory health returns. 
Subjects who discontinue the active dosing phase  of the study due to adverse event(s) or 
other safety concerns will not be replaced. 
When the decision is made to discontinue a subject’s participation in the study, no further 
investigational product medication should be ad ministered. Every attempt should be made to 
complete all required study evaluations and procedures. Reasons for all withdrawals should be recorded on the CRF. 
The investigator may withdraw a subject from the THR-1442-C-453 trial for any of the 
following reasons: 
• A protocol violation occurs, or 
• A serious or intolerable adverse event occurs, or 
• A clinically significant change in a laboratory parameter occurs, or 
• The sponsor or investigator terminates the study, or 
• The subject requests to be discontinued from the study. 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 33 of 58 Subjects who do not complete the study but who have received investigational product 
should have a follow-up examination, including a complete physical examination, vital signs, 
ECG and clinical laboratory tests if clinically indicated according to Section 7 . 
6.10 Appropriateness of Measurements 
PK and safety parameters in this protocol are standard assessments and are widely used and 
generally recognized as reliable, accurate, and relevant measurements. 
Determination of urinary glucose is a non-i nvasive and quantitative method that allows 
immediate assessment of the PD effects of an SGLT2 inhibitor. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 34 of 58 7 STUDY ACTIVITIES 
7.1 Screening (Days -28 to Day -1) 
During the screening period, the following infor mation will be gathered and the indicated 
procedures will be performed: 
• Content of informed consent will be explain ed to the subject and the signed informed 
consent collected.  
• Medical history and demographic information will be obtained.  
• Physical examination will be conducted, includi ng height and weight measurements as 
described in Section 6.3 . 
• Vital signs will be measured, including pulse , temperature, respiratory rate, and blood 
pressure taken in the sitting position after at least 5 min of rest as described in Section 
6.4. 
• 12-lead ECG will be taken in the supine positi on after at least 5 min of rest as described 
in Section 6.5 . 
• Clean-catch, mid-stream urine will be co llected for urinalysis as described in Section 
6.6.2.2 . If urine is dipstick positive for leukocyte esterase or nitrites, sample is to be sent 
for microscopic evaluation and culture.  
• Urine screen will be conducted for drug a buse and cotinine. If the drug screen is 
conducted more than 5 days pre-dose, the drug screen must be repeated prior to dosing. 
Drug abuse testing includes amphetamines, ba rbiturates, cocaine metabolites, opiates, 
benzodiazepines, and cannabinoids.  
• All female subjects will receive urine pregnancy test. 
• Blood will be drawn for hematology, serum chemistry, and serology as detailed in 
Section 6.6.2.1 . 
• Inclusion/exclusion criteria will be evalu ated based on the information collected at the 
screening examination. 
 
7.2 Period 1 
7.2.1 Day 0 (Clinic Admission) 
The following information will be gathered and the indicated procedures will be performed: 
• If screening was conducted more than five days prior to dosing, the inclusion and 
exclusion criteria must be confirmed and a urine drug screen performed. 
• All female subjects will receive urine pregnancy test. 
• Partial PE will be performed as described in Section 6.3 . 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 35 of 58 • If the subject is still eligible based on the study inclusion and exclusion criteria, the 
subject will be admitted and randomized into the study. 
• Concomitant medications and adverse event in formation will be collected as appropriate. 
• Pre-dose urine collection in 12 h batches will begin with the -12 h to 0 h batch for 
baseline analysis of creatinine and fo r UGE (PD) analysis as described in Section 6.6.2.3 . 
 
7.2.2 Day 1 (Dosing Day) : Pre-dose Activities 
The following information will be gathered and the indicated procedures will be performed 
pre-dose: 
• Vital signs will be recorded pre-dose. 
• 12-lead ECG will be taken in the supine posit ion after at least 5 min of rest pre-dose. 
• Pre-dose urine will be collected until 0 h (-12 h to 0 h batch) fo r baseline UGE and 
creatinine analysis as described in Section 6.6.2.3 . 
• Urine sample will be collected for pre-dose urinalysis as described in Section 6.6.2.2 . If 
urine is dipstick positive for leukocyte ester ase or nitrites, sample is to be sent for 
microscopic evaluation and culture. 
• Pre-dose blood will be drawn for hematology, and serum chemistry as detailed in Section 
6.6.2.1 . 
• Pre-dose plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4.  
• Pre-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.2.3 Day 1 (Dosing Day): Dosing 
• For Group 1 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, metformin, 1000 mg, alone or bexagliflozin and metformin in combination will be 
administered prior to first meal of the day as detailed in Section 5.3.1 . 
• For Group 2 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, glimepiride, 4 mg, alone or bexagliflozin and glimepiride in combination will be 
administered prior to first meal of the day with glucose solution as detailed in Section 
5.3.2 . 
• For Group 3 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, sitagliptin, 100 mg, alone or bexagliflozin and sitagliptin in combination will be administered prior to first meal of the day as detailed in Section 5.3.3 . 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 36 of 58 7.2.4 Day 1: Post-dose Activities 
• Vital signs will be recorded at 4 h post-dose. 
• 12-lead ECG will be taken in the supine position after at least 5 min of rest at 4 h post-
dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 0.5, 1, 2, 
3, 4, 5, 6, 8, 10, 12, 16 h post-dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 0 to 12 h 
and 12 to 24 h post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.2.5 Day 2: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 24 and 36 
h post-dose.   
• Urine for analysis of creatinine and UGE will  be collected in 12 h batches 12 to 24 h, 24 
to 36 h and 36 to 48 h as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.2.6 Day 3: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 48 h post-
dose for all Groups and additionally at 60 h post-dose for Group 3.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 36 to 48 h 
post-dose for all Groups and additionally at 48 to 60 h and 60 to 72 h post-dose for Group 
3 as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
• For Group 1 and 2, vital signs will be recorded at 48 h post-dose. 
• For Group 1 and 2, urine will be collec ted for urinalysis as described in Section 6.6.2.2 . 
• For Group 1 and 2, blood will be drawn for hematology and serum chemistry as detailed 
in Section 6.6.2.1.  
• For Group 1 and 2, the subject will be discharg ed after completion of all activities and 
scheduled for admission for Period 2. 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 37 of 58 7.2.7 Day 4 (Group 3 Only): Post-dose Activities 
• Vital signs will be recorded at 72 h post-dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 72 h post-
dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 60 to 72 h 
post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
• Urine will be collected for urinalysis as described in Section 6.6.2.2 . 
• Blood will be drawn for hematology and serum chemistry as detailed in Section 6.6.2.1.  
• Subject will be discharged after completion of all activities and scheduled for admission 
for Period 2. 
 For subjects who are terminated from the study for any reason after dosing, all activities for 
the study termination day except for PK and PD sample collection must be completed. The 
reason for termination must be en tered onto the case report form. 
7.3 Period 2 
7.3.1 Day 7 (Clinic Admission) 
The following information will be gathered and the indicated procedures will be performed: 
• All female subjects will receive urine pregnancy test. 
• If the subject is still eligible based on the study inclusion and exclusion criteria, the 
subject will be admitted. 
• Concomitant medications and adverse event in formation will be collected as appropriate. 
• Pre-dose urine collection in 12 h batches will begin with the -12 h to 0 h batch for 
baseline analysis of creatinine and fo r UGE (PD) analysis as described in Section 6.6.2.3 . 
 
7.3.2 Day 8 (Dosing Day) : Pre-dose Activities 
The following information will be gathered and the indicated procedures will be performed 
pre-dose: 
• Vital signs will be recorded pre-dose. 
• 12-lead ECG will be taken in the supine posit ion after at least 5 min of rest pre-dose. 
• Pre-dose urine will be collected until 0 h (-12 h to 0 h batch) for baseline UGE and 
creatinine analysis as described in Section 6.6.2.3 . 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 38 of 58 • Urine sample will be collected for pre-dose urinalysis as described in Section 6.6.2.2 . If 
urine is dipstick positive for leukocyte ester ase or nitrites, sample is to be sent for 
microscopic evaluation and culture. 
• Pre-dose blood will be drawn for hematology, and serum chemistry as detailed in Section 
6.6.2.1 . 
• Pre-dose plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4.  
• Pre-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.3.3 Day 8 (Dosing Day): Dosing 
• For Group 1 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, metformin, 1000 mg, alone or bexagliflozin and metformin in combination will be 
administered prior to first meal of the day as detailed in Section 5.3.1 . 
• For Group 2 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, glimepiride, 4 mg, alone or bexagliflozin and glimepiride in combination will be 
administered prior to first meal of the day with glucose solution as detailed in Section 
5.3.2 . 
• For Group 3 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, sitagliptin, 100 mg, alone or bexagliflozin and sitagliptin in combination will be 
administered prior to first meal of the day as detailed in Section 5.3.3 . 
 
7.3.4 Day 8 (Dosing Day) : Post-dose Activities 
• Vital signs will be recorded at 4 h post-dose. 
• 12-lead ECG will be taken in the supine position after at least 5 min of rest at 4 h post-
dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 0.5, 1, 2, 
3, 4, 5, 6, 8, 10, 12, 16 h post-dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 0 to 12 h 
and 12 to 24 h post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.3.5 Day 9: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 24 and 36 
h post-dose.   
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 39 of 58 • Urine for analysis of creatinine and UGE will be collected in 12 h batches 12 to 24 h, 24 
to 36 h and 36 to 48 h as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.3.6 Day 10: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 48 h post-
dose for all Groups and additionally at 60 h post-dose for Group 3.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 36 to 48 h 
post-dose for all Groups and additionally at 48 to 60 h and 60 to 72 h post-dose for Group 
3 as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and adverse event information will be collected as 
appropriate. 
• For Group 1 and 2, vital signs will be recorded at 48 h post-dose. 
• For Group 1 and 2, urine will be collec ted for urinalysis as described in Section 6.6.2.2 . 
• For Group 1 and 2, blood will be drawn for hematology and serum chemistry as detailed 
in Section 6.6.2.1.  
• For Group 1 and 2, the subject will be discharg ed after completion of all activities and 
scheduled for admission for Period 3. 
 
7.3.7 Day 11 (Group 3 Only): Post-dose Activities 
• Vital signs will be recorded at 72 h post-dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 72 h post-
dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 60 to 72 h 
post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
• Urine will be collected for urinalysis as described in Section 6.6.2.2 . 
• Blood will be drawn for hematology and serum chemistry as detailed in Section 6.6.2.1.  
• Subject will be discharged after completion of all activities and scheduled for admission 
for Period 3. 
 For subjects who are terminated from the study for any reason after dosing, all activities for 
the study termination day except for PK and PD  sample collection must be completed. The 
reason for termination must be entered onto the case report form. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 40 of 58 7.4 Period 3 
7.4.1 Day 14 (Clinic Admission) 
The following information will be gathered and the indicated procedures will be performed: 
• All female subjects will receive urine pregnancy test. 
• If the subject is still eligible based on the study inclusion and exclusion criteria, the 
subject will be admitted. 
• Concomitant medications and adverse event in formation will be collected as appropriate. 
• Pre-dose urine collection in 12 h batches will begin with the -12 h to 0 h batch for 
baseline analysis of creatinine and fo r UGE (PD) analysis as described in Section 6.6.2.3 . 
 
7.4.2 Day 15 (Dosing Day): Pre-dose Activities 
The following information will be gathered and the indicated procedures will be performed 
pre-dose: 
• Vital signs will be recorded pre-dose. 
• 12-lead ECG will be taken in the supine posit ion after at least 5 min of rest pre-dose. 
• Pre-dose urine will be collected until 0 h (-12 h to 0 h batch) for baseline UGE creatinine 
analysis as described in Section 6.6.2.3 . 
• Urine sample will be collected for pre-dose urinalysis as described in Section 6.6.2.2 . If 
urine is dipstick positive for leukocyte ester ase or nitrites, sample is to be sent for 
microscopic evaluation and culture. 
• Pre-dose blood will be drawn for hematology, and serum chemistry as detailed in Section 
6.6.2.1 . 
• Pre-dose plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4.  
• Pre-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.4.3 Day 15 (Dosing Day): Dosing 
• For Group 1 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, metformin, 1000 mg, alone or bexagliflozin and metformin in combination will be 
administered prior to first meal of the day as detailed in Section 5.3.1 . 
• For Group 2 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, glimepiride, 4 mg, alone or bexagliflo zin and glimepiride in combination will be 
administered prior to first meal of the day with glucose solution as detailed in Section 
5.3.2 . 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 41 of 58 • For Group 3 subjects, after an overnight fast of at least 10 h, bexagliflozin tablets, 20 mg, 
alone, sitagliptin, 100 mg, alone or bexagliflozin and sitagliptin in combination will be 
administered prior to first meal of the day as detailed in Section 5.3.3 . 
 
7.4.4 Day 15 (Dosing Day) : Post-dose Activities 
• Vital signs will be recorded at 4 h post-dose. 
• 12-lead ECG will be taken in the supine position after at least 5 min of rest at 4 h post-
dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 0.5, 1, 2, 
3, 4, 5, 6, 8, 10, 12, 16 h post-dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 0 to 12 h 
and 12 to 24 h post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.4.5 Day 16: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 24 and 36 
h post-dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches 12 to 24 h, 24 
to 36 h and 36 to 48 h as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
 
7.4.6 Day 17: Post-dose Activities 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 48 h post-
dose for all Groups and additionally at 60 h post-dose for Group 3.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 36 to 48 h 
post-dose for all Groups and additionally at 48 to 60 h and 60 to 72 h post-dose for Group 
3 as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
• For Group 1 and 2, vital signs will be recorded at 48 h post-dose. 
• For Group 1 and 2, urine will be collec ted for urinalysis as described in Section 6.6.2.2 . 
• For Group 1 and 2, blood will be drawn for hematology and serum chemistry as detailed 
in Section 6.6.2.1.  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 42 of 58 • For Group 1 and 2, a physical examination will be conducted as described in Section 6.3 . 
• For Group 1 and 2, a 12-lead ECG will be taken in the supine position after at least 5 min 
of rest as described in Section 6.5 . 
• For Group 1 and 2, the subject will be discha rged after completion of all activities. 
 
7.4.7 Day 18 (Group 3 Only): Post-dose Activities 
• Vital signs will be recorded at 72 h post-dose. 
• Plasma samples will be drawn for PK analysis as detailed in Section 6.6.2.4  at 72 h post-
dose.   
• Urine for analysis of creatinine and UGE will be collected in 12 h batches at 60 to 72 h 
post-dose as described in Section 6.6.2.3 . 
• Post-dose concomitant medications and advers e event information will be collected as 
appropriate. 
• Urine will be collected for urinalysis as described in Section 6.6.2.2 . 
• Blood will be drawn for hematology and serum chemistry as detailed in Section 6.6.2.1 . 
• Physical examination will be conducted as described in Section 6.3 . 
• 12-lead ECG will be taken in the supine positi on after at least 5 min of rest as described 
in Section 6.5 . 
• Subject will be discharged after completion of all activities. 
 For subjects who are terminated from the study for any reason after dosing, all activities for 
the study termination day except for PK and PD  sample collection must be completed. The 
reason for termination must be entered onto the case report form. 
7.5 Early Termination or Follow-up Procedures 
Subjects who have completed study activities or  have withdrawn consen t and have received 
investigational product should have a follow-up examination if clinically indicated, including a complete physical examination, vital signs, ECG, and clinical laboratory tests (hematology, and serum chemistry). The sponsor must be notified in the event that a subject withdraws or has been withdrawn from the study. 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 43 of 58 8 QUALITY CONTROL AND ASSURANCE 
The clinical research facility will be monit ored by the study monitor to ensure correct 
performance of the study procedures and assure th at the study will be conducted according to 
the protocol and relevant regulatory requirements. CRF entries will be verified with the source documentation. 
Quality control principles will be applied throughout the performance of this study by 
following the standard operating procedure (SOP s) of the contract research organization 
(CRO) and the sponsor. Review procedures w ill be implemented at the CRO for all 
documents that are generated in relation to the study. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 44 of 58 9 PLANNED STATISTICAL METHODS 
9.1 General Considerations 
The statistical evaluation of PK parameters wi ll be conducted by the designated CRO. A 
detailed Statistical and Analytical Plan will be  generated prior to any PK, PD or statistical 
analysis of the data. Statistical  analysis will be performed using Statistical Analysis Software 
SAS for Windows® (SAS Institute Inc., USA). Non- compartmental analysis will be 
performed using Phoenix®WinNonlin® 6.4 (Certara, USA). 
9.2 Determination of Sample Size 
The sample size for this study is not based upon formal statistical consideration. The sample 
size is considered adequate to characterize the PK of bexagliflozin and OHAs, to assess 
potential drug-drug interactions, and to provide safety and tolerability data on bexagliflozin 
when administered alone and in combination with OHAs. 
9.3 Analysis Populations 
9.3.1 Safety Population 
The Safety Population will include all randomized subjects who received at least one dose of 
investigational product. Subjects will be an alyzed according to the treatment received. 
9.3.2 PK Population 
The PK Population will include all randomized subjects who receive at least one dose of 
investigational product and who have su fficient plasma bexagliflozin and OHA 
measurements to derive PK parameters following dosing. The PK Population will be used to summarize the PK parameters. 
9.3.3 PD Population 
The PD Population will include all randomized subjects who receive at least one dose of 
investigational product and will have had at least 2 batches of 12 h urine collection from 
which to calculate UGE measurement following dosing. The PD Population will be used to summarize the PD parameters. 
9.4 Demographics and Baseline Characteristics 
Baseline characteristics will be summarized  for all subjects in the Safety, PK and PD 
Populations. Descriptive statistics will be performed. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 45 of 58 9.5 Pharmacokinetic Analysis 
9.5.1 Calculation of Phar macokinetic Variables 
A non-compartmental analysis will be used to  calculate the PK parameters of bexagliflozin, 
metformin, glimepiride and sitagliptin individuall y and the combination of bexagliflozin with 
each tested OHA using the software Phoenix® WinNonlin® 6.4 (Certara, USA). From the 
plasma bexagliflozin concentration-time data, the following PK parameters will be estimated for each subject where feasible. 
C
max:  Maximum observed plasma concentration 
Tmax:  Time of maximum observed plasma concentration 
Oz:   Terminal elimination phase rate constant 
T½:   Apparent terminal elimination half life 
CL/F:  Apparent oral clearance V
z/F:  Apparent volume of distribution 
AUC 0-t: Area under the plasma concentration-time curve from Time 0 to Time t (time of 
last quantifiable plasma concentration) 
AUC 0-∞: Area under the plasma concentration-time curve from Time 0 to infinity 
Cmax and T max will be obtained directly from expe rimental observations. If multiple maxima 
occur at equal concentrations, the first temporal value will be taken as the C max and T max. 
The apparent terminal elimination half-life, T 1/2, where determinable, will be calculated as 
the natural log of 2 divided by the terminal phase rate constant, λz. The number of data points 
included in the regression will be determine d by visual inspection, but a minimum of three 
data points in the terminal phase, excluding C max, is required to estimate λz. In order for the 
selection to take place the adjusted r2 value reported in Phoenix®WinNonlin® must be ≥ 0.7.  
AUC 0-t and AUC 0-∞ will be calculated using the lin ear trapezoidal linear interpolation 
method, using actual elapsed time values. If the actual collection time is unknown the nominal collection time may be used for the purposes of PK parameter estimation. For the purpose of calculating AUC, all missing values will  be treated as missing in the PK analysis 
and excluded from analysis except when they oc cur at pre-dose where they will be set to 
zero. All values that were below the limit of quantitation (BLOQ) prior to T
max will be set to 
zero. BLOQ values that occur after T max will be set to missing. When ≥ 2 consecutive plasma 
concentrations BLOQ are encountered after T max, these and all subsequent values will be 
excluded from the analysis.  
AUC 0-∞ will be calculated according to the following equation: 
AUC 0-∞= AUC last + (C last / λz), where C last is the last temporal quantifiable plasma 
concentration corresponding to T last. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 46 of 58 The proportion of AUC 0-∞ due to extrapolation (AUC extr) will be calculated and expressed as 
a percentage. AUC 0-∞ values will be considered unreliable estimates if the AUC extr is greater 
than 20%. 
CL/F will be calculated as Dose/AUC 0-∞. 
Vz/F will be calculated as Dose/( λz × AUC 0-∞). 
T½ will be calculated as 0.693/ λz. 
Descriptive statistics for the plasma concentrat ions of bexagliflozin, metformin, glimepiride 
and sitagliptin by Treatment and Timepoint  will be provided. A listing of plasma 
concentrations by Subject Number, Treatment Period and Timepoint will also be provided. 
9.5.2 Statistical Analysis of Pharmacokinetic Variables 
To assess the effect of OHAs metformin, glimepir ide or sitagliptin on the PK of bexagliflozin 
and vice versa, an analyses of variance (ANOVA ) using a linear mixed-effects model will be 
fitted to the natural logarithmic transfor mation of PK parameters of bexagliflozin (C max, 
AUC 0-t and AUC 0-∞). The linear mixed-effects model will  include subject as a random effect, 
and treatment, period, and sequence as fixed ef fects. The 90% confiden ce intervals will be 
constructed for the (bexagliflozin and OHA in  combination) to (bexagliflozin alone) or 
(OHA alone) ratio of the least squares (LS) geometric means of PK parameters (C max, AUC 0-t 
and AUC 0-∞), with 80-125% defined as the lack of interaction boundaries. 
Descriptive statistics for the PK parameters C max, Tmax, AUC 0-∞ , AUC 0-t , CL/F,  Vz/F, λz, and 
T1/2 will be tabulated by treatment. Means, st andard deviations, medians, ranges (min, max) 
and geometric means and coefficients of variati on will be presented for all PK parameters 
with the exception of T max. Medians and ranges will be presented for T max.  
A listing of derived PK parameters of bexagliflo zin by Subject ID and Treatment Period will 
be provided.  
9.6 Pharmacodynamic Analysis 
Urinary glucose excretion will be determined as a PD parameter at baseline and up to 72 h post-dose. The drug-drug interaction effect between bexagliflozin and OHAs will be evaluated by comparing the mean cumulative UG E between subjects taking bexagliflozin or 
OHA alone and bexagliflozin and OHA in combination. 
Descriptive statistics on the PD parameters will  be performed. The effect of an OHA on the 
cumulative UGE between subjects administered bexagliflozin alone or in combination with 
an OHA will be compared. The PD parameters, UGE and UGE normalized by urinary creatinine, including UGE
t1-t2, in 12-hour and 24 –hour increments, and total 24-hour UGE, 
will be determined. UGE t1-t2 (mg) will be derived from urine volume (V t1-t2, mL) × glucose 
concentration (mg/dL) / 100. UGE will be lis ted and summarized by treatment arm using 
descriptive statistics. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 47 of 58 9.7 Safety Analysis 
Safety data will include AEs, PE results, vital signs, ECG results, and clinical lab results, 
including serum chemistry, hematology, and urin alysis. Observed data will be described as 
counts and percentages for discrete variables  and estimation of means, standard deviations 
(SDs), medians, inter-quartile range, minimum and maximum for continuous metrics. All 
subjects in the Safety Population will be included in the safety analyses. All safety data will be presented in by-subject listings and included in the clinical trial report. 
9.7.1 Adverse Events 
Adverse events will be mapped to preferred term and body system using the Medical 
Dictionary for Regulatory Activities (MedDR A). The number and percentage of subjects 
reporting adverse events will be determined by  relationship to treatment and by severity of 
the event. Drug-related adverse events will be  considered those to be possibly related to 
bexagliflozin administration. 
Adverse event listings will be provided for the following subsets: 
• all treatment emergent AEs (TEAEs). 
• all TEAEs at least possibly related to bexagliflozin. 
• serious TEAEs (if any). 
• TEAEs leading to study discontinuation (if any). 
 
AEs are dosing emergent if they occur on or after bexagliflozin administration. TEAEs will 
be considered at least possibly related to bexagliflozin based on the investigator’s  
assessment. Only TEAEs will be tabulated in summary tables. If the AE(s) onset date-time or 
date occurs after the first dose up until right before the next dose, the AE(s) will be assigned to the first treatment. Any AE(s) that occur after the second dose up until the follow-up visit will be assigned to the second treatment. 
Tabulations will display TEAEs by severi ty and relationship to bexagliflozin. 
9.7.2 Hypoglycemia 
Hypoglycemia as defined in Section 6.7.4.4  will be presented in listings and summarized. 
9.7.3 Clinical and Laboratory Events and Analyses 
Clinical and laboratory metrics are measured at  baseline (pre-dose measurement of each 
period) and during the treatment periods ( Appendix 1 ). These variables include vital signs 
(blood pressure, respiration, temperature), clinical laboratory results (see Section 6.6  for a 
complete list), and ECGs. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 48 of 58 Serum chemistry, hematology, and urinalysis (quantitative parameters) data will be 
summarized for each treatmen t period. Summaries for change from baseline will be 
presented for these laboratory tests.  
ECG results will be summarized as changes from  baseline in intervals . Abnormalities as well 
as changes from previous assessment will be listed. 
9.7.4 Concomitant Medications 
Concomitant medications will be coded us ing the World Health Organization Drug 
Dictionary (WHO-DD). A by-subject listing of concomitant medications will include all 
medications taken during the study. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 49 of 58 10 ADMINISTRATIVE CONSIDERATIONS 
10.1 Investigators and Study Administrative Structure 
Information regarding key personnel involved in the conduct of the study, including names 
and contact details of participating investigators, monitors, clinical laboratories, and technical departments and/or institutions, as well as information on members of additional study 
committees, will be found in the study files of the investigational site. 
10.2 Institutional Review Board (IRB) or Independent Ethics Committee 
(IEC) Approval 
The study protocol, informed consent document, relevant supporting information, and all 
types of subject recruitment or advertisement information must be submitted to the IRB/IEC 
for review and must be approved by the sponsor and the IRB/IEC before the study is initiated. Any amendments or addenda to the prot ocol must also be approved by the IRB/IEC 
prior to implementing changes in the study. The investigator is responsible for keeping the IRB/IEC informed of the progress of the study and of any changes made to the protocol as deemed appropriate. The investigator must also keep the IRB/IEC informed of any SAEs occurring to subjects under their supervision. 
10.3 Ethical Conduct of the Study 
The procedures set out in this protocol pertaining to the conduct, evaluation, and documentation of this study are designed to ensure that the sponsor and investigator follow 
Good Clinical Practice (GCP) Guidelines and the guiding principles detailed in the 
Declaration of Helsinki. The study will also be  carried out in keeping with applicable local 
laws and regulations. An inspection by the sponsor representatives and/or their designee 
and/or healthy authority or other authorized regulatory authorities representatives may occur at any time. The investigator must agree to th e inspection of study-related records by the 
regulatory authority/sponsor representatives, and must allow direct access to source documents to the regulatory authority/sponsor representatives. 
The investigator is responsible for complying with the protocol and all appropriate 
regulations and guidelines governing global clin ical research. Additionally, he/she is 
responsible for ensuring that all participating staff members are adequately trained and competent to perform his/her assigned tasks. 
Modifications to the study protocol will not be implemented by either the sponsor or the 
investigator without agreement by both parties. However, the investigator may implement a 
deviation from or a change of the protocol to eliminate any immediate hazards to the trial subjects without prior IRB/IEC or sponsor approval/favorable opinion. As soon as possible, the implemented deviation or change, the reasons  for it, and if appropriate, the proposed 
protocol amendment should be submitted to the head of the investigational site, IRB (via the 
head of the investigational site)/sponsor. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 50 of 58 Any deviations from the protocol must be fully explained and documented by the 
investigator. The circumstances, action taken, and impact of the deviation on the trial must be communicated by the principal investigator to the designated medical monitor. Any subsequent actions will be assessed by the designated medical monitor and documented. 
10.4 Subject Information and Consent 
The investigator will draft the informed consent form based on the protocol and CRO’s draft 
informed consent form . The sponsor will review the investigator’s draft informed consent 
form prior to submission to the IRB/IEC and the final IRB/IEC approved document must be 
provided to the sponsor for regulatory purposes. 
Prior to the beginning of the study, the investigator must have received from the IEC or IRB 
the written approval or favorable opinion of the informed consent form and any other written 
information to be provided to subjects. The written approval of the IRB/IEC together with the approved subject information and informed consent forms must be filed. The informed consent form must contain all elements required by the Federal Drug Administration under 
21 Code of Federal Regulations Part 50 and the ICH GCP Guidelines (E6), in addition to, any other elements required by re gulations or institutional policy. 
Written informed consent must be obtained before any study-specific procedure takes place. 
Participation in the study and date of informed consent given by the subject should be documented appropriately in the subject’s files.  A copy of the signed informed consent form 
must be provided to the subject. If applicable, it will be provided in a certified translation in the language understood by the subject, if not English. Signed consent forms must remain in each subject’s study file and must be available for  verification by study monitors at any time.  
10.5 Subject Confidentiality 
The information obtained during the conduct of this clinical study is confidential, and 
disclosure to third parties other than those noted below is prohibited. Information obtained during the conduct of this study will be used by the sponsor in connection with the development of the investigational product. The study investigator is obliged to provide the 
sponsor with complete test results and all data developed in this study. Subject-specific information may be provided to other appropriate medical personnel only with the subject’s 
permission. To ensure compliance with current ICH guidelines, data generated by this study must be available for inspection upon request by  representatives of national and local health 
authorities, the sponsor, and the IRB/IEC for each study site. 
Subject names and other identifiers, such as photographs, audio, or videotapes, may not be 
disclosed in any publication without prior written authorization from the subject. 
10.6 Study Monitoring 
An authorized sponsor representative will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
national and local government regulations and guidelines. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 51 of 58 The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to inspect facilities and records relevant to this study. 
10.7 Case Report Forms and Study Records 
For each subject consented, a case report form (C RF), in paper or electronic format, will be 
supplied and maintained by the CRO staff and signed by the investigator or authorized designee to indicate that he/she has reviewed and agrees with the entered data. This also applies to those subjects who fail to comple te the trial. The reason a subject is withdrawn 
must be recorded in the case report form. 
Entries made in the CRF must be verifiable against source documents. Source documents are 
defined as all medical records, medical not es, laboratory results, ECG traces and any 
additional document other than the CRF that has original subject information contained within it. 
All CRFs and source documents should be completed following GCPs and the CRO’s 
standard operating procedures. 
10.8 Protocol Violations/Deviations 
It is important to conduct the study according to the protocol. Protocol deviations will not be 
prospectively granted by the sponsor. If deviations occur, such as a visit or sampling window being missed, the investigator must decide whet her to proceed, for example, whether or not 
to complete the visit or sample collection outside of the protocol-defined window. The 
sponsor’s medical monitor must be notified immediately when protocol deviations are 
discovered so that a decision about whether to keep the subject in the study can be made. 
Only when an emergency occurs that requires a departure from the protocol for an individual 
subject will there be such a departure without the sponsor’s pre -approval. The nature and 
reasons for the protocol deviation will be rec orded in the subject’s CRF, and the principal 
investigator must notify the Sponsor. 
Protocol violations must be reported in the final study report. 
10.9 Access to Source Documentation 
Authorized sponsor representatives will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
local and national government regulations and guidelines. 
The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to inspect facilities and records relevant to this study. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 52 of 58 The center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP, and legal aspects. This w ill include on-site checking of the CRFs for 
completeness and clarity, cross-checking with source documents, and clarification of administrative matters. 
All CRF data will be entered into a clinical database. Following the correction of any errors, 
the clinical database will be locked. 
10.10 Retention of Data 
The study file and all source data should be retained until notification is given by the sponsor for destruction. 
If the investigator withdraws from the trial a nd relinquishes his/her responsibility for the 
maintenance and retention of records, he/she must notify the sponsor in writing so that arrangements can be made to properly store the trial materials. 
10.11 Publication and Disclosure Policy 
All data and results and all intellectual property rights in the data and results derived from the 
study will be the property of the sponsor, who may utilize the data in various ways, such as for submission to government regulatory authorities or disclosure to other investigators. 
No publication or disclosure of study results w ill be permitted except as specified in a 
separate, written agreement between Theracos Sub, LLC and the investigator. If results of this study are reported in medical journals or at  meetings, all subjects’ identities will remain 
confidential. 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016     
 
Confidential Page 53 of 58 11 REFERENCE LIST 
IDF (2014). International Diabetes Federation Diabetes Atlas, 6th Edition. 
 Langtry, H.D., and Balfour, J.A. (1998). Glimep iride. A review of its use in the management 
of type 2 diabetes mellitus. Drugs  55, 563-584. 
 Nauck, M.A. (2014). Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy  8, 1335-1380. 
 Pentikainen, P.J., Neuvonen, P.J., and Pentti la, A. (1979). Pharmacokinetics of metformin 
after intravenous and oral administration to man. European journal of clinical pharmacology  
16, 195-202. 
 
Tahrani, A.A., Barnett, A.H., and Bailey, C.J. (2016). Pharmacology and therapeutic 
implications of current drugs for type 2 diabetes mellitus. Nature reviews Endocrinology.  Vincent, S.H., Reed, J.R., Bergman, A.J., Elmore, C.S., Zhu, B., Xu, S., Ebel, D., Larson, P.,  Zeng, W., Chen, L. , et al.  (2007). Metabolism and excretion of the dipeptidyl peptidase 4 
inhibitor [14C]sitagliptin in humans. Drug metab olism and disposition: the biological fate of  
chemicals  35, 533-538. 
 Zhang, W., Welihinda, A., Mechanic, J., Ding, H., Zhu, L., Lu, Y., Deng, Z., Sheng, Z., Lv, B., Chen, Y. , et al.  (2011). EGT1442, a potent and selective SGLT2 inhibitor, attenuates 
blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone 
rats. Pharmacol Res  63, 284-293. 
 
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016  
   
 
Confidential Page 54 of 58 Appendix 1 Schedule of Events 
A. S CHEDULE OF EVENTS FOR STUDY 1: BEXAGLIFLOZIN AND METFORMIN DRUG-DRUG INTERACTION  
 Screening Period 1 Period 2 Period 3 
Study activity D -28 
to -1 D0 D1 
pre-
dose D1 
post-
dose D2 D3 D71 D8 
pre-
dose D8 
post-
dose D9 D10 D141 D15 
pre-
dose D15 
post-
dose D16 D17 
Informed consent form X                
Screening for I/E 
criteria X X     X     X     
Physical examination2 X X              X 
Medical history and 
demographics X                
Randomization  X               
Admission/discharge  X    X X    X X    X 
Vital signs3 X  X X  X  X X  X  X X  X 
ECG4 X  X X    X X    X X  X 
Urinalysis5 X  X   X  X   X  X   X 
Blood draw for clinical 
lab tests6 X  X   X  X   X  X   X 
Blood sample for PK7   X X X X  X X X X  X X X X 
Urine collection for PD8  X X X X X X X X X X X X X X X 
Urine Pregnancy Test X X     X     X     
Adverse event and 
concomitant medication  X X X X X X X X X X X X X X X 
Study completion                X 
1 The admission day for Period 2 and 3 will be 4-6 days after discharge from the previous Period. 
2 A complete physical examination will be performed at screening and day 17 prior to discharge. A partial physical exam will be p erformed on admission day of Period 1. 
3 On days 1, 8 and 15, vital signs will be determined at pre-dose and at 4 h and 48 h (day 3, 10 and 17) post-dose. 
4 ECG data will be recorded at screening, on days 1, 8 and 15 at pre-dose and at 4 h post-dose, at the study termination visit an d when clinically indicated. 
5 Urine samples will be collected for urinalysis at screening, pre-dose and prior to discharge. If urine is dipstick positive for  leukocyte esterase or nitrites, sample will be sent for microscopic 
evaluation and culture. Urine drug screen will only be performed at screening, and if it is conducted more than 5 days prior to  dosing, screening shall be repeated.  
6 Blood samples will be drawn for clinical laboratory tests at screening, pre-dose and prior to discharge. Clinical laboratory te sts are listed in Table 2 . 
7 Plasma samples for PK analysis will be collected as described in Section 6.6.2.4 . 
8 Urine collection for the evaluation of urinary glucose and creatinine are described in Section 6.6.2.3 .  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016  
   
 
Confidential Page 55 of 58 B. S CHEDULE OF EVENTS FOR STUDY 2: BEXAGLIFLOZIN AND GLIMEPIRIDE DRUG-DRUG INTERACTION  
 Screening Period 1 Period 2 Period 3 
Study activity  D -28 
to -1 D0 D1 
pre-
dose D1 
post-
dose D2 D3 D71 D8 
pre-
dose D8 
post-
dose D9 D10 D141 D15 
pre-
dose D15 
post-
dose D16 D17 
Informed consent form X                
Screening for I/E 
criteria X X     X     X     
Physical examination2 X X              X 
Medical history and 
demographics X                
Randomization  X               
Admission/discharge  X    X X    X X    X 
Vital signs3 X  X X  X  X X  X  X X  X 
ECG4 X  X X    X X    X X  X 
Urinalysis5 X  X   X  X   X  X   X 
Blood draw for clinical 
lab tests6 X  X   X  X   X  X   X 
Blood sample for PK7   X X X X  X X X X  X X X X 
Urine collection for PD8  X X X X X X X X X X X X X X X 
Urine Pregnancy Test X X     X     X     
Adverse event and 
concomitant medication  X X X X X X X X X X X X X X X 
Study completion                X 
1 The admission day for Period 2 and 3 will be 4-6 days after discharge from the previous Period. 
2 A complete physical examination will be performed at screening and day 17 prior to discharge. A partial physical exam will be p erformed on admission day of Period 1. 
3 On days 1, 8 and 15, vital signs will be determined at pre-dose and at 4 h and 48 h (day 3, 10 and 17) post-dose. 
4 ECG data will be recorded at screening, on days 1, 8 and 15 at pre-dose and at 4 h post-dose, at the study termination visit an d when clinically indicated. 
5 Urine samples will be collected for urinalysis at screening, pre-dose and prior to discharge. If urine is dipstick positive for  leukocyte esterase or nitrites, sample will be sent for microscopic 
evaluation and culture. Urine drug screen will only be performed at screening, and if it is conducted more than 5 days prior to  dosing, screening shall be repeated.  
6 Blood samples will be drawn for clinical laboratory tests at screening, pre-dose and prior to discharge. Clinical laboratory te sts are listed in Table 2 . 
7 Plasma samples for PK analysis will be collected as described in Section 6.6.2.4 . 
8 Urine collection for the evaluation of urinary glucose and creatinine are described in Section 6.6.2.3 . 
  
Bexagliflozin tablets  Theracos Sub, LLC 
Clinical Trial Protocol: THR-1442-C-453  01 September 2016  
   
 
Confidential Page 56 of 58 C. S CHEDULE OF EVENTS FOR STUDY 3: BEXAGLIFLOZIN AND SITAGLIPTIN DRUG-DRUG INTERACTION  
 Screening Period 1 Period 2 Period 3 
Study activity  D -28 
to -1 D0 D1 
pre-
dose D1 
post-
dose D2 D3 D4 D71 D8 
pre-
dose D8 
post-
dose D9 D10 D11 D141 D15 
pre-
dose D15 
post-
dose D16 D17 D18 
Informed consent form X                   
Screening for I/E 
criteria X X      X      X      
Physical examination2 X X                 X 
Medical history and 
demographics X                   
Randomization  X                  
Admission/discharge  X     X X     X X     X 
Vital signs3 X  X X   X  X X   X  X X   X 
ECG4 X  X X     X X     X X   X 
Urinalysis5 X  X    X  X    X  X    X 
Blood draw for clinical 
lab tests6 X  X    X  X    X  X    X 
Blood sample for PK7   X X X X X  X X X X X  X X X X X 
Urine collection for PD8  X X X X X X X X X X X X X X X X X X 
Urine Pregnancy Test X X      X      X      
Adverse event and 
concomitant medication  X X X X X X X X X X X X X X X X X X 
Study completion                   X 
1 The admission day for Period 2 and 3 will be 4-6 days after discharge from the previous Period. 
2 A complete physical examination will be performed at screening a nd day 17 prior to discharge. A partial physical exam will be p erformed on admission day of Period 1. 
3 On days 1, 8 and 15, vital signs will be determined at pre-dose and at 4 h and 72 h (day 4, 11 and 18) post-dose. 
4 ECG data will be recorded at screening, on days 1, 8 and 15 at pre-dose and at 4 h post-dose, at the study termination visit an d when clinically indicated. 
5 Urine samples will be collected for urinalysis at screening, pre- dose and prior to discharge. If urine is dipstick positive for  leukocyte esterase or nitrites, sample will be sent 
for microscopic evaluation and culture. Urine drug screen will only be performed at screening, and if it is conducted more than  5 days prior to dosing, screening shall be 
repeated.  
6 Blood samples will be drawn for clinical laboratory tests at screening, pre-dose and prior to discharge. Clinical laboratory te sts are listed in Table 2 . 
7 Plasma samples for PK analysis will be collected as described in Section 6.6.2.4 . 
8 Urine collection for the evaluation of urin ary glucose and creatinine are described in Section 6.6.2.3 . 